| Year |
Citation |
Score |
| 2024 |
Roselle C, Horikawa I, Chen L, Kelly AR, Gonzales D, Da T, Wellhausen N, Rommel PC, Baker D, Suhoski M, Scholler J, O'Connor RS, Young RM, Harris CC, June CH. Enhancing chimeric antigen receptor T cell therapy by modulating the p53 signaling network with Δ133p53α. Proceedings of the National Academy of Sciences of the United States of America. 121: e2317735121. PMID 38408246 DOI: 10.1073/pnas.2317735121 |
0.506 |
|
| 2024 |
Vittayawacharin P, Kongtim P, Chu Y, June CH, Bollard CM, Ciurea SO. Adoptive cellular therapy after hematopoietic stem cell transplantation. American Journal of Hematology. PMID 38269484 DOI: 10.1002/ajh.27204 |
0.457 |
|
| 2024 |
Ghilardi G, Fraietta JA, Gerson JN, Van Deerlin VM, Morrissette JJD, Caponetti GC, Paruzzo L, Harris JC, Chong EA, Susanibar Adaniya SP, Svoboda J, Nasta SD, Ugwuanyi OH, Landsburg DJ, Fardella E, ... ... June CH, et al. T-cell Lymphoma and Secondary Primary Malignancy Risk After Commercial CAR T-cell Therapy. Nature Medicine. PMID 38266761 DOI: 10.1038/s41591-024-02826-w |
0.5 |
|
| 2024 |
Levine BL, Pasquini MC, Connolly JE, Porter DL, Gustafson MP, Boelens JJ, Horwitz EM, Grupp SA, Maus MV, Locke FL, Ciceri F, Ruggeri A, Snowden J, Heslop HE, Mackall CL, ... June CH, et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nature Medicine. PMID 38195751 DOI: 10.1038/s41591-023-02767-w |
0.644 |
|
| 2023 |
Tsuchida CA, Brandes N, Bueno R, Trinidad M, Mazumder T, Yu B, Hwang B, Chang C, Liu J, Sun Y, Hopkins CR, Parker KR, Qi Y, Hofman L, Satpathy AT, ... ... June CH, et al. Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells. Cell. 186: 4567-4582.e20. PMID 37794590 DOI: 10.1016/j.cell.2023.08.041 |
0.339 |
|
| 2023 |
Agarwal S, Aznar MA, Rech AJ, Good CR, Kuramitsu S, Da T, Gohil M, Chen L, Hong SA, Ravikumar P, Rennels AK, Salas-Mckee J, Kong W, Ruella M, Davis MM, ... ... June CH, et al. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells. Immunity. 56: 2388-2407.e9. PMID 37776850 DOI: 10.1016/j.immuni.2023.09.001 |
0.574 |
|
| 2023 |
Bobisse S, Bianchi V, Tanyi JL, Sarivalasis A, Missiaglia E, Pétremand R, Benedetti F, Torigian DA, Genolet R, Barras D, Michel A, Mastroyannis SA, Zsiros E, Dangaj Laniti D, Tsourti Z, ... ... June CH, et al. A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer. Nature Cancer. PMID 37735588 DOI: 10.1038/s43018-023-00623-x |
0.335 |
|
| 2023 |
Noll JH, Levine BL, June CH, Fraietta JA. Beyond youth: Understanding CAR T cell fitness in the context of immunological aging. Seminars in Immunology. 70: 101840. PMID 37729825 DOI: 10.1016/j.smim.2023.101840 |
0.445 |
|
| 2023 |
Berjis A, Muthumani D, Sheppard NC, June CH. Swiss army knife T cell: one T cell many tumor targets. Cell Research. PMID 37666977 DOI: 10.1038/s41422-023-00871-7 |
0.463 |
|
| 2023 |
Wellhausen N, O'Connell RP, Lesch S, Engel NW, Rennels AK, Gonzales D, Herbst F, Young RM, Garcia KC, Weiner D, June CH, Gill SI. Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy. Science Translational Medicine. eadi1145. PMID 37651540 DOI: 10.1126/scitranslmed.adi1145 |
0.601 |
|
| 2023 |
Tang Y, Liu W, Kadu S, Johnson O, Hasanali ZS, Kelly AR, Shestov AA, Greenblat E, Holmes M, Wang LP, Shih N, O'Connor RS, Garfall A, Allman D, Vogl DT, ... ... June CH, et al. Exploiting the CD200-CD200R Immune Checkpoint Axis in Multiple Myeloma to Enhance CAR-T Therapy. Blood. PMID 37616575 DOI: 10.1182/blood.2022018658 |
0.53 |
|
| 2023 |
Xiao Z, Todd L, Huang L, Noguera-Ortega E, Lu Z, Huang L, Kopp M, Li Y, Pattada N, Zhong W, Guo W, Scholler J, Liousia M, Assenmacher CA, June CH, et al. Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors. Nature Communications. 14: 5110. PMID 37607999 DOI: 10.1038/s41467-023-40850-5 |
0.515 |
|
| 2023 |
Hamilton AG, Swingle KL, Joseph RA, Mai D, Gong N, Billingsley MM, Alameh MG, Weissman D, Sheppard NC, June CH, Mitchell MJ. Lonizable Lipid Nanoparticles with Integrated Immune Checkpoint Inhibition for mRNA CAR T Cell Engineering. Advanced Healthcare Materials. e2301515. PMID 37602495 DOI: 10.1002/adhm.202301515 |
0.323 |
|
| 2023 |
Baker DJ, Arany Z, Baur JA, Epstein JA, June CH. CAR T therapy beyond cancer: the evolution of a living drug. Nature. 619: 707-715. PMID 37495877 DOI: 10.1038/s41586-023-06243-w |
0.38 |
|
| 2023 |
Shah PD, Huang AC, Xu X, Orlowski R, Amaravadi RK, Schuchter LM, Zhang P, Tchou J, Matlawski T, Cervini A, Shea J, Gilmore J, Lledo L, Dengel K, Marshall A, ... ... June CH, et al. Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma. Cancer Research Communications. 3: 821-829. PMID 37377890 DOI: 10.1158/2767-9764.CRC-22-0486 |
0.335 |
|
| 2023 |
Uslu U, June CH. T-cell Therapies Targeting Multiple Cancer Antigens: The Power of Many. Cancer Immunology Research. OF1. PMID 37347991 DOI: 10.1158/2326-6066.CIR-23-0160 |
0.342 |
|
| 2023 |
Haas AR, Golden RJ, Litzky LA, Engels B, Zhao L, Xu F, Taraszka JA, Ramones M, Granda B, Chang WJ, Jadlowsky J, Shea KM, Runkle A, Chew A, Dowd E, ... ... June CH, et al. Two Cases of Severe Pulmonary Toxicity from Highly Active Mesothelin-Directed CAR T Cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 37312454 DOI: 10.1016/j.ymthe.2023.06.006 |
0.342 |
|
| 2023 |
Glisovic-Aplenc T, Diorio C, Chukinas JA, Veliz K, Shestova O, Shen F, Nunez-Cruz S, Vincent TL, Miao F, Milone MC, June CH, Teachey DT, Tasian SK, Aplenc R, Gill SI. CD38 as a pan-hematologic target for chimeric antigen receptor T cells. Blood Advances. PMID 37171449 DOI: 10.1182/bloodadvances.2022007059 |
0.595 |
|
| 2023 |
Guo W, Zhong W, Xiao Z, Qin Z, Yang J, Wen Y, Yu Z, Li Y, Sheppard NC, Fuchs SY, Xu X, Herlyn M, June CH, Pure E. Tumor-derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors. Cancer Research. PMID 37115855 DOI: 10.1158/0008-5472.CAN-22-2220 |
0.379 |
|
| 2023 |
Xiao Z, Lu Z, Todd L, Huang L, Kopp M, Huang L, Zhong W, Li Y, Guo W, Scholler J, June CH, Albelda SM, Pur E. Disruption of desmoplastic stroma overcomes restrictions to T cell extravasation, immune exclusion and immunosuppression in solid tumors. Biorxiv : the Preprint Server For Biology. PMID 37090547 DOI: 10.1101/2023.04.13.536777 |
0.504 |
|
| 2023 |
Watanabe K, Aznar MA, Kuramitsu S, Siurala M, Da T, Agarwal S, Song D, Scholler J, Rotolo A, Posey AD, Rook AH, Haun PL, Ruella M, Young RM, June CH. Identifying highly active anti-CCR4-CAR T cells for the treatment of T-cell lymphoma. Blood Advances. PMID 37058474 DOI: 10.1182/bloodadvances.2022008327 |
0.552 |
|
| 2023 |
Tsuchida CA, Brandes N, Bueno R, Trinidad M, Mazumder T, Yu B, Hwang B, Chang C, Liu J, Sun Y, Hopkins CR, Parker KR, Qi Y, Satpathy AT, Stadtmauer EA, ... ... June CH, et al. Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells. Biorxiv : the Preprint Server For Biology. PMID 36993359 DOI: 10.1101/2023.03.22.533709 |
0.335 |
|
| 2023 |
June CH. The Unlikely Development of CAR T Cells: a Brief History and Prospects for the Future. The Keio Journal of Medicine. 72: 26. PMID 36967127 DOI: 10.2302/kjm.ABSTRACT_72_1-1 |
0.354 |
|
| 2023 |
Mai D, Johnson O, Reff J, Fan TJ, Scholler J, Sheppard NC, June CH. Combined disruption of T cell inflammatory regulators Regnase-1 and Roquin-1 enhances antitumor activity of engineered human T cells. Proceedings of the National Academy of Sciences of the United States of America. 120: e2218632120. PMID 36920923 DOI: 10.1073/pnas.2218632120 |
0.478 |
|
| 2023 |
Uribe-Herranz M, Beghi S, Ruella M, Parvathaneni K, Salaris S, Kostopoulos N, George SS, Pierini S, Krimitza E, Costabile F, Ghirardi G, Amelsberg KV, Lee YG, Pajarillo R, Markmann C, ... ... June CH, et al. Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 36641624 DOI: 10.1016/j.ymthe.2023.01.012 |
0.513 |
|
| 2023 |
Uslu U, Da T, Assenmacher CA, Scholler J, Young RM, Tchou J, June CH. Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinoma. Science Advances. 9: eade2526. PMID 36630514 DOI: 10.1126/sciadv.ade2526 |
0.33 |
|
| 2022 |
Smole A, Benton A, Poussin MA, Eiva MA, Mezzanotte C, Camisa B, Greco B, Sharma P, Minutolo NG, Gray F, Bear AS, Baroja ML, Cummins C, Xu C, Sanvito F, ... ... June CH, et al. Expression of inducible factors reprograms CAR-T cells for enhanced function and safety. Cancer Cell. 40: 1470-1487.e7. PMID 36513049 DOI: 10.1016/j.ccell.2022.11.006 |
0.423 |
|
| 2022 |
Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, Gao P, Bandyopadhyay S, Sun H, Zhao Z, Lundh S, Pruteanu-Malinici I, Nobles CL, Maji S, Frey NV, ... ... June CH, et al. Author Correction: Decade-long leukaemia remissions with persistence of CD4 CAR T cells. Nature. PMID 36477542 DOI: 10.1038/s41586-022-05376-8 |
0.49 |
|
| 2022 |
Baker DJ, June CH. CAR T therapy extends its reach to autoimmune diseases. Cell. 185: 4471-4473. PMID 36423579 DOI: 10.1016/j.cell.2022.10.026 |
0.368 |
|
| 2022 |
Garfall AL, Cohen AD, Susanibar-Adaniya SP, Hwang WT, Vogl DT, Waxman AJ, Lacey SF, Gonzalez VE, Fraietta JA, Gupta M, Kulikovskaya I, Tian L, Chen F, Koterba N, Bartoszek RL, ... ... June CH, et al. Anti-BCMA/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy. Blood Cancer Discovery. PMID 36413381 DOI: 10.1158/2643-3230.BCD-22-0074 |
0.435 |
|
| 2022 |
Newman H, Li Y, Liu H, Myers RM, Tam V, DiNofia A, Wray L, Rheingold SR, Callahan C, White C, Baniewicz D, Winestone LE, Kadauke S, Diorio C, June CH, et al. Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy. Blood. PMID 36351239 DOI: 10.1182/blood.2022017866 |
0.38 |
|
| 2022 |
Castelli S, Young RM, June CH. Off-the-shelf CAR T cells to treat cancer. Cell Research. 32: 1036-1037. PMID 36329201 DOI: 10.1038/s41422-022-00745-4 |
0.404 |
|
| 2022 |
Smith M, Dai A, Ghilardi G, Amelsberg KV, Devlin SM, Pajarillo R, Slingerland JB, Beghi S, Herrera PS, Giardina P, Clurman A, Dwomoh E, Armijo G, Gomes ALC, Littmann ER, ... ... June CH, et al. Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nature Medicine. PMID 36253610 DOI: 10.1038/s41591-022-02069-7 |
0.46 |
|
| 2022 |
Dhodapkar KM, Cohen AD, Kaushal A, Garfall AL, Manalo RJ, Carr AR, McCachren SS, Stadtmauer EA, Lacey SF, Melenhorst JJ, June CH, Milone MC, Dhodapkar MV. Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma. Blood Cancer Discovery. OF1-OF12. PMID 36026513 DOI: 10.1158/2643-3230.BCD-22-0018 |
0.526 |
|
| 2022 |
Lee IK, Noguera-Ortega E, Xiao Z, Todd L, Scholler J, Song D, Liousia M, Lohith K, Xu K, Edwards KJ, Farwell MD, June CH, Albelda SM, Pure E, Sellmyer MA. Monitoring Therapeutic Response to Anti-Fibroblast Activation Protein (FAP) CAR T Cells using [18F]AlF-FAPI-74. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35972732 DOI: 10.1158/1078-0432.CCR-22-1379 |
0.448 |
|
| 2022 |
Uslu U, June CH. CAR T-cell Therapy Meets Clonal Hematopoiesis. Blood Cancer Discovery. OF1-OF3. PMID 35896010 DOI: 10.1158/2643-3230.BCD-22-0067 |
0.398 |
|
| 2022 |
Diorio C, Shraim R, Myers R, Behrens EM, Canna S, Bassiri H, Aplenc R, Burudpakdee C, Chen F, DiNofia AM, Gill S, Gonzalez V, Lambert MP, Barz Leahy A, Levine BL, ... ... June CH, et al. Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell Associated Neurotoxicity Syndrome in B-Cell ALL Patients Receiving CART19. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35705524 DOI: 10.1158/1078-0432.CCR-22-0822 |
0.305 |
|
| 2022 |
Kalbasi A, Siurala M, Su LL, Tariveranmoshabad M, Picton LK, Ravikumar P, Li P, Lin JX, Escuin-Ordinas H, Da T, Kremer SV, Sun AL, Castelli S, Agarwal S, Scholler J, ... ... June CH, et al. Potentiating adoptive cell therapy using synthetic IL-9 receptors. Nature. PMID 35676488 DOI: 10.1038/s41586-022-04801-2 |
0.302 |
|
| 2022 |
Bai Z, Woodhouse S, Zhao Z, Arya R, Govek K, Kim D, Lundh S, Baysoy A, Sun H, Deng Y, Xiao Y, Barrett DM, Myers RM, Grupp SA, June CH, et al. Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL. Science Advances. 8: eabj2820. PMID 35675405 DOI: 10.1126/sciadv.abj2820 |
0.528 |
|
| 2022 |
Finck AV, Blanchard T, Roselle CP, Golinelli G, June CH. Engineered cellular immunotherapies in cancer and beyond. Nature Medicine. 28: 678-689. PMID 35440724 DOI: 10.1038/s41591-022-01765-8 |
0.337 |
|
| 2022 |
Young RM, Engel NW, Uslu U, Wellhausen N, June CH. Next-Generation CAR T-cell Therapies. Cancer Discovery. OF1-OF14. PMID 35417527 DOI: 10.1158/2159-8290.CD-21-1683 |
0.542 |
|
| 2022 |
Gill SI, Frey NV, Hexner E, Metzger S, O'Brien M, Hwang WT, Brogdon JL, Davis MM, Fraietta JA, Gaymon A, Gladney WL, Lacey SF, Lamontagne A, Mato AR, Maus MV, ... ... June CH, et al. Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia. Blood Advances. PMID 35349631 DOI: 10.1182/bloodadvances.2022007317 |
0.611 |
|
| 2022 |
Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, Davis MM, Hwang WT, Lal P, Carpenter EL, Maude SL, Plesa G, Vapiwala N, Chew A, Moniak M, Sebro RA, ... ... June CH, et al. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nature Medicine. PMID 35314843 DOI: 10.1038/s41591-022-01726-1 |
0.461 |
|
| 2022 |
Feng Z, He X, Zhang X, Wu Y, Xing B, Knowles A, Shan Q, Miller S, Hojnacki T, Ma J, Katona BW, Gade TPF, Schrader J, Metz DC, June CH, et al. Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues. Nature Cancer. PMID 35314826 DOI: 10.1038/s43018-022-00344-7 |
0.413 |
|
| 2022 |
Smith M, Dai A, Ghilardi G, Amelsberg KV, Devlin SM, Pajarillo R, Slingerland JB, Beghi S, Herrera PS, Giardina P, Clurman A, Dwomoh E, Armijo G, Gomes ALC, Littmann ER, ... ... June CH, et al. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nature Medicine. PMID 35288695 DOI: 10.1038/s41591-022-01702-9 |
0.468 |
|
| 2022 |
Giles JR, Manne S, Freilich E, Oldridge DA, Baxter AE, George S, Chen Z, Huang H, Chilukuri L, Carberry M, Giles L, Weng NP, Young RM, June CH, Schuchter LM, et al. Human epigenetic and transcriptional T cell differentiation atlas for identifying functional T cell-specific enhancers. Immunity. 55: 557-574.e7. PMID 35263570 DOI: 10.1016/j.immuni.2022.02.004 |
0.468 |
|
| 2022 |
Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, Gao P, Bandyopadhyay S, Sun H, Zhao Z, Lundh S, Pruteanu-Malinici I, Nobles CL, Maji S, Frey NV, ... ... June CH, et al. Decade-long leukaemia remissions with persistence of CD4 CAR T cells. Nature. PMID 35110735 DOI: 10.1038/s41586-021-04390-6 |
0.562 |
|
| 2022 |
Rurik JG, Tombácz I, Yadegari A, Méndez Fernández PO, Shewale SV, Li L, Kimura T, Soliman OY, Papp TE, Tam YK, Mui BL, Albelda SM, Puré E, June CH, Aghajanian H, et al. CAR T cells produced in vivo to treat cardiac injury. Science (New York, N.Y.). 375: 91-96. PMID 34990237 DOI: 10.1126/science.abm0594 |
0.303 |
|
| 2021 |
Wang H, Chen H, Liu S, Zhang J, Lu H, Somasundaram R, Choi R, Zhang G, Ou L, Scholler J, Tian S, Dong L, Yeye G, Huang L, Connelly T, ... ... June CH, et al. Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function. Journal For Immunotherapy of Cancer. 9. PMID 34937742 DOI: 10.1136/jitc-2021-003339 |
0.499 |
|
| 2021 |
Good CR, Aznar MA, Kuramitsu S, Samareh P, Agarwal S, Donahue G, Ishiyama K, Wellhausen N, Rennels AK, Ma Y, Tian L, Guedan S, Alexander KA, Zhang Z, Rommel PC, ... ... June CH, et al. An NK-like CAR T cell transition in CAR T cell dysfunction. Cell. PMID 34861191 DOI: 10.1016/j.cell.2021.11.016 |
0.532 |
|
| 2021 |
Wellhausen N, Agarwal S, Rommel PC, Gill SI, June CH. Better living through chemistry: CRISPR/Cas engineered T cells for cancer immunotherapy. Current Opinion in Immunology. 74: 76-84. PMID 34798542 DOI: 10.1016/j.coi.2021.10.008 |
0.42 |
|
| 2021 |
Dorff TB, Narayan V, Forman SJ, Zang PD, Fraietta JA, June CH, Haas NB, Priceman SJ. Novel Redirected T-Cell Immunotherapies for Advanced Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34675084 DOI: 10.1158/1078-0432.CCR-21-1483 |
0.325 |
|
| 2021 |
Billingsley MM, Hamilton AG, Mai D, Patel SK, Swingle KL, Sheppard NC, June CH, Mitchell MJ. Orthogonal Design of Experiments for Optimization of Lipid Nanoparticles for mRNA Engineering of CAR T Cells. Nano Letters. PMID 34669421 DOI: 10.1021/acs.nanolett.1c02503 |
0.434 |
|
| 2021 |
Garcia-Canaveras JC, Heo D, Trefely S, Leferovich J, Xu C, Philipson BI, Ghassemi S, Milone MC, Moon EK, Snyder NW, June CH, Rabinowitz JD, O'Connor RS. CAR T-Cells Depend on the Coupling of NADH Oxidation with ATP Production. Cells. 10. PMID 34571983 DOI: 10.3390/cells10092334 |
0.451 |
|
| 2021 |
Leahy AB, Newman H, Li Y, Liu H, Myers R, DiNofia A, Dolan JG, Callahan C, Baniewicz D, Devine K, Wray L, Aplenc R, June CH, Grupp SA, Rheingold SR, et al. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials. The Lancet. Haematology. 8: e711-e722. PMID 34560014 DOI: 10.1016/S2352-3026(21)00238-6 |
0.51 |
|
| 2021 |
Manjunath SH, Cohen AD, Lacey SF, Davis MM, Garfall AL, Melenhorst JJ, Maxwell R, Arscott WT, Maity A, Jones JA, Plastaras JP, Stadtmauer EA, Levine BL, June CH, Milone MC, et al. The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34526365 DOI: 10.1158/1078-0432.CCR-21-0308 |
0.39 |
|
| 2021 |
Qazilbash MH, Saini NY, Soung-Chul C, Wang Z, Stadtmauer E, Baladandayuthapani V, Lin H, Tross B, Honhar M, Rao SS, Kim K, Popescu M, Szymura SJ, Zhang T, Anderson AJ, ... ... June CH, et al. A Randomized Phase II Trial of Idiotype Vaccination and Adoptive Autologous T-Cell Transfer in Multiple Myeloma patients. Blood. PMID 34521108 DOI: 10.1182/blood.2020008493 |
0.42 |
|
| 2021 |
Johnson LR, Lee DY, Eacret JS, Ye D, June CH, Minn AJ. The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function. Cell. PMID 34464586 DOI: 10.1016/j.cell.2021.08.004 |
0.469 |
|
| 2021 |
Kong W, Dimitri A, Wang W, Jung IY, Ott CJ, Fasolino M, Wang Y, Kulikovskaya I, Gupta M, Yoder T, DeNizio JE, Everett JK, Williams EF, Xu J, Scholler J, ... ... June CH, et al. BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. The Journal of Clinical Investigation. 131. PMID 34396987 DOI: 10.1172/JCI145459 |
0.864 |
|
| 2021 |
Levine JE, Grupp SA, Pulsipher MA, Dietz AC, Rives S, Myers GD, August KJ, Verneris MR, Buechner J, Laetsch TW, Bittencourt H, Baruchel A, Boyer MW, De Moerloose B, Qayed M, ... ... June CH, et al. Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. Journal For Immunotherapy of Cancer. 9. PMID 34353848 DOI: 10.1136/jitc-2020-002287 |
0.328 |
|
| 2021 |
Thakur A, Scholler J, Kubicka E, Bliemeister ET, Schalk DL, June CH, Lum LG. Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells. Frontiers in Immunology. 12: 690437. PMID 34290709 DOI: 10.3389/fimmu.2021.690437 |
0.426 |
|
| 2021 |
Myers RM, Li Y, Barz Leahy A, Barrett DM, Teachey DT, Callahan C, Fasano CC, Rheingold SR, DiNofia A, Wray L, Aplenc R, Baniewicz D, Liu H, Shaw PA, Pequignot E, ... ... June CH, et al. Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2003458. PMID 34156874 DOI: 10.1200/JCO.20.03458 |
0.521 |
|
| 2021 |
Durgin JS, Henderson F, Nasrallah MP, Mohan S, Wang S, Lacey SF, Melenhorst JJ, Desai AS, Lee JYK, Maus MV, June CH, Brem S, O'Connor RS, Binder Z, O'Rourke DM. Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma. Frontiers in Oncology. 11: 669071. PMID 34026647 DOI: 10.3389/fonc.2021.669071 |
0.663 |
|
| 2021 |
Bai Z, Lundh S, Kim D, Woodhouse S, Barrett DM, Myers RM, Grupp SA, Maus MV, June CH, Camara PG, Melenhorst JJ, Fan R. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells. Journal For Immunotherapy of Cancer. 9. PMID 34006631 DOI: 10.1136/jitc-2020-002328 |
0.733 |
|
| 2021 |
Singh N, Frey NV, Engels B, Barrett DM, Shestova O, Ravikumar P, Cummins KD, Lee YG, Pajarillo R, Chun I, Shyu A, Highfill SL, Price A, Zhao L, Peng L, ... ... June CH, et al. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. Nature Medicine. PMID 33888899 DOI: 10.1038/s41591-021-01326-5 |
0.506 |
|
| 2021 |
Agarwal S, Wellhausen N, Levine BL, June CH. Production of Human CRISPR-Engineered CAR-T Cells. Journal of Visualized Experiments : Jove. PMID 33779622 DOI: 10.3791/62299 |
0.534 |
|
| 2021 |
Bernabei L, Tian L, Garfall AL, Melenhorst JJ, Lacey SF, Stadtmauer EA, Vogl DT, Gonzalez VE, Plesa G, Young RM, Waxman A, Levine BL, June CH, Milone MC, Cohen AD. B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy. British Journal of Haematology. PMID 33713436 DOI: 10.1111/bjh.17397 |
0.423 |
|
| 2021 |
He X, Feng Z, Ma J, Zhang X, Ling S, Cao Y, Xing B, Wu Y, Wang L, Katona BW, June CH, Hua X. CAR T cells targeting CD13 controllably induce eradication of acute myeloid leukemia with a single domain antibody switch. Leukemia. PMID 33712688 DOI: 10.1038/s41375-021-01208-2 |
0.422 |
|
| 2021 |
Tebas P, Jadlowsky JK, Shaw PA, Tian L, Esparza E, Brennan A, Kim S, Naing SY, Richardson MW, Vogel AN, Maldini CR, Kong H, Liu X, Lacey SF, Bauer AM, ... ... June CH, et al. CCR5-edited CD4 T cells augment HIV-specific immunity to enable post rebound control of HIV replication. The Journal of Clinical Investigation. PMID 33571163 DOI: 10.1172/JCI144486 |
0.411 |
|
| 2021 |
Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu AC, Wang Y, O'Connor RS, Hwang WT, Pequignot E, Ambrose DE, Zhang C, Wilcox N, Bedoya F, ... ... June CH, et al. Author Correction: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nature Medicine. PMID 33547459 DOI: 10.1038/s41591-021-01248-2 |
0.8 |
|
| 2021 |
Gong N, Sheppard NC, Billingsley MM, June CH, Mitchell MJ. Nanomaterials for T-cell cancer immunotherapy. Nature Nanotechnology. 16: 25-36. PMID 33437036 DOI: 10.1038/s41565-020-00822-y |
0.484 |
|
| 2020 |
Chaudhury A, Zhu X, Chu L, Goliaei A, June CH, Kearns JD, Stein AM. Chimeric Antigen Receptor T Cell Therapies: A Review of Cellular Kinetic-Pharmacodynamic Modeling Approaches. Journal of Clinical Pharmacology. 60: S147-S159. PMID 33205434 DOI: 10.1002/jcph.1691 |
0.512 |
|
| 2020 |
Jacobson JM, Jadlowsky JK, Lacey SF, Fraietta JA, Plesa G, Chono H, Lee DH, Kulikovskaya I, Bartoszek C, Chen F, Dimitri A, Levine BL, Veloso EA, Hwang WT, June CH. Autologous CD4 T Lymphocytes Modified with a Tat-Dependent, Virus-Specific Endoribonuclease Gene in HIV-Infected Individuals. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 33186691 DOI: 10.1016/j.ymthe.2020.11.007 |
0.465 |
|
| 2020 |
Parker KR, Migliorini D, Perkey E, Yost KE, Bhaduri A, Bagga P, Haris M, Wilson NE, Liu F, Gabunia K, Scholler J, Montine TJ, Bhoj VG, Reddy R, Mohan S, ... ... June CH, et al. Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies. Cell. PMID 32961131 DOI: 10.1016/J.Cell.2020.08.022 |
0.584 |
|
| 2020 |
Ghassemi S, Martinez-Becerra FJ, Master AM, Richman SA, Heo D, Leferovich J, Tu Y, García-Cañaveras JC, Ayari A, Lu Y, Wang A, Rabinowitz JD, Milone MC, June CH, O'Connor RS. Enhancing Chimeric Antigen Receptor T Cell Anti-tumor Function through Advanced Media Design. Molecular Therapy. Methods & Clinical Development. 18: 595-606. PMID 32775494 DOI: 10.1016/J.Omtm.2020.07.008 |
0.586 |
|
| 2020 |
Ko AH, Jordan AC, Tooker E, Lacey SF, Chang RB, Li Y, Venook AP, Tempero M, Damon L, Fong L, O'Hara MH, Levine BL, Melenhorst JJ, Plesa G, June CH, et al. Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 32730744 DOI: 10.1016/J.Ymthe.2020.07.017 |
0.609 |
|
| 2020 |
Castellarin M, Sands C, Da T, Scholler J, Graham K, Buza E, Fraietta JA, Zhao Y, June CH. A rational mouse model to detect on-target off-tumor CAR T cell toxicity. Jci Insight. PMID 32544101 DOI: 10.1172/Jci.Insight.136012 |
0.425 |
|
| 2020 |
Thakur A, Scholler J, Schalk DL, June CH, Lum LG. Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept study. Journal of Cancer Research and Clinical Oncology. PMID 32449004 DOI: 10.1007/S00432-020-03260-4 |
0.617 |
|
| 2020 |
Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, Schmierer M, Gabrusiewicz K, Anderson NR, Petty NE, Cummins KD, Shen F, Shan X, Veliz K, Blouch K, ... ... June CH, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nature Biotechnology. PMID 32361713 DOI: 10.1038/S41587-020-0462-Y |
0.409 |
|
| 2020 |
Moore BJB, June CH. Cytokine release syndrome in severe COVID-19. Science (New York, N.Y.). PMID 32303591 DOI: 10.1126/Science.Abb8925 |
0.314 |
|
| 2020 |
Agarwal S, June CH. Harnessing CAR T Cell Insights to Develop Treatments for Hyperinflammatory Responses in COVID-19 patients. Cancer Discovery. PMID 32303509 DOI: 10.1158/2159-8290.Cd-20-0473 |
0.39 |
|
| 2020 |
Frey NV, Gill S, Hexner EO, Schuster S, Nasta S, Loren A, Svoboda J, Stadtmauer E, Landsburg DJ, Mato A, Levine BL, Lacey SF, Melenhorst JJ, Veloso E, Gaymon A, ... ... June CH, et al. Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1903237. PMID 32298202 DOI: 10.1200/Jco.19.03237 |
0.513 |
|
| 2020 |
Philipson BI, O'Connor RS, May MJ, June CH, Albelda SM, Milone MC. 4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling. Science Signaling. 13. PMID 32234960 DOI: 10.1126/Scisignal.Aay8248 |
0.608 |
|
| 2020 |
Guedan S, Madar A, Casado-Medrano V, Shaw CE, Wing A, Liu F, Young RM, June CH, Posey AD. Single residue in CD28-costimulated CAR T cells limits long-term persistence and antitumor durability. The Journal of Clinical Investigation. PMID 32069268 DOI: 10.1172/Jci133215 |
0.634 |
|
| 2020 |
Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, Tian L, Gonzalez VE, Xu J, Jung IY, Melenhorst JJ, ... ... June CH, et al. CRISPR-engineered T cells in patients with refractory cancer. Science (New York, N.Y.). PMID 32029687 DOI: 10.1126/Science.Aba7365 |
0.547 |
|
| 2020 |
Singh N, Lee YG, Shestova O, Ravikumar P, Hayer KE, Hong SJ, Lu XM, Pajarillo R, Agarwal S, Kuramitsu S, Orlando EJ, Mueller KT, Good CR, Berger SL, Shalem O, ... ... June CH, et al. Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T cell dysfunction. Cancer Discovery. PMID 32001516 DOI: 10.1158/2159-8290.Cd-19-0813 |
0.577 |
|
| 2020 |
He X, Feng Z, Ma J, Ling S, Cao Y, Gurung B, Wu Y, Katona BW, O'Dwyer KP, Siegel DL, June CH, Hua X. Bi-specific and Split CAR T Cells Targeting CD13 and TIM3 Eradicate Acute Myeloid Leukemia. Blood. PMID 31951650 DOI: 10.1182/Blood.2019002779 |
0.642 |
|
| 2020 |
Billingsley M, Singh N, Ravikumar P, Zhang R, June CH, Mitchell MJ. Ionizable Lipid Nanoparticle Mediated mRNA Delivery for Human CAR T Cell Engineering. Nano Letters. PMID 31951421 DOI: 10.1021/Acs.Nanolett.9B04246 |
0.554 |
|
| 2020 |
Newman H, Leahy AEB, Li Y, Liu H, Myers RM, DiNofia AM, Dolan JG, Callahan C, Devine KJ, Wray L, June CH, Grupp SA, Rheingold SR, Maude SL. CD19-targeted chimeric antigen receptor (CAR) T cells in CNS relapsed acute lymphoblastic leukemia (ALL). Journal of Clinical Oncology. 38: 10511-10511. DOI: 10.1200/Jco.2020.38.15_Suppl.10511 |
0.545 |
|
| 2020 |
Shah PD, Huang ACC, Xu X, Zhang PJ, Orlowski R, Matlawski T, Shea J, Cervini A, Amaravadi RK, Tchou JC, Schuchter LM, Wherry EJ, Linette GP, Mick R, Kulikovskaya I, ... ... June CH, et al. Phase I trial of autologous cMET-directed CAR-t cells administered intravenously in patients with melanoma & breast carcinoma. Journal of Clinical Oncology. 38: 10035-10035. DOI: 10.1200/Jco.2020.38.15_Suppl.10035 |
0.502 |
|
| 2020 |
Klichinsky M, Ruella M, Shestova O, Best A, Blouch K, Lu XM, Kenderian SS, Kim MY, O'Connor R, Wallace S, Kozlowski M, Marchione DM, Shestov M, Garcia BA, June C, et al. Abstract PR07: Human chimeric antigen receptor (CAR) macrophages for cancer immunotherapy Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm18-Pr07 |
0.478 |
|
| 2020 |
Castellarin M, Sands C, Young R, June C. A novel switchable car-T cell therapy for tumor retargeting and improved safety Cytotherapy. 22. DOI: 10.1016/J.Jcyt.2020.03.487 |
0.587 |
|
| 2020 |
Xu J, Gohil M, Stadtmauer E, Fraietta J, Gonzalez V, Salas-McKee J, Jadlowsky J, Gladney W, Lamontagne A, Fesnak A, Siegel D, Levine B, Lacey S, June C, Davis M. Characterization of autologous T cells engineered to express NY-ESO-1 TCR with multiplexed CRISPR/Cas9 editing (NYCE T Cells) Cytotherapy. 22: S35-S36. DOI: 10.1016/J.Jcyt.2020.03.027 |
0.627 |
|
| 2020 |
Gladney W, Hexner E, Salas-McKee J, Fesnak A, Jadlowsky J, Plesa G, Leskowitz R, Chew A, Dai A, Gohil M, Xu J, Siegel D, Lacey S, Davis M, June C. Pre-clinical development of multiplex-CRISPR-edited cell and gene therapy products Cytotherapy. 22: S35. DOI: 10.1016/J.Jcyt.2020.03.026 |
0.577 |
|
| 2019 |
Nobles CL, Sherrill-Mix S, Everett JK, Reddy S, Fraietta JA, Porter DL, Frey N, Gill SI, Grupp SA, Maude SL, Siegel DL, Levine BL, June CH, Lacey SF, Melenhorst JJ, et al. CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. The Journal of Clinical Investigation. PMID 31845905 DOI: 10.1172/Jci130144 |
0.505 |
|
| 2019 |
Frey NV, Shaw PA, Hexner EO, Pequignot E, Gill S, Luger SM, Mangan JK, Loren AW, Perl AE, Maude SL, Grupp SA, Shah NN, Gilmore J, Lacey SF, Melenhorst JJ, ... ... June CH, et al. Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1901892. PMID 31815579 DOI: 10.1200/Jco.19.01892 |
0.445 |
|
| 2019 |
Garfall AL, June CH. Trispecific antibodies offer a third way forward for anticancer immunotherapy. Nature. 575: 450-451. PMID 31740852 DOI: 10.1038/D41586-019-03495-3 |
0.449 |
|
| 2019 |
Pillai V, Muralidharan K, Meng W, Bagashev A, Oldridge DA, Rosenthal J, Van Arnam J, Melenhorst JJ, Mohan D, DiNofia AM, Luo M, Cherian S, Fromm JR, Wertheim G, Thomas-Tikhonenko A, ... ... June CH, et al. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Blood Advances. 3: 3539-3549. PMID 31738832 DOI: 10.1182/Bloodadvances.2019000692 |
0.601 |
|
| 2019 |
Stadtmauer EA, Cohen AD, Weber K, Lacey SF, Gonzalez VE, Melenhorst JJ, Fraietta JA, Plesa G, Shea J, Matlawski T, Cervini A, Mangan P, Gaymon A, Desjardins S, Lancaster E, ... ... June CH, et al. First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma. Blood. 134: 49. PMID 31724015 DOI: 10.1182/Blood-2019-122374 |
0.737 |
|
| 2019 |
Aghajanian H, Kimura T, Rurik JG, Hancock AS, Leibowitz MS, Li L, Scholler J, Monslow J, Lo A, Han W, Wang T, Bedi K, Morley MP, Saldana RAL, Bolar NA, ... ... June CH, et al. Author Correction: Targeting cardiac fibrosis with engineered T cells. Nature. PMID 31723271 DOI: 10.1038/S41586-019-1761-7 |
0.397 |
|
| 2019 |
Ruella M, Barrett DM, Shestova O, Perazzelli J, Posey AD, Hong SJ, Kozlowski M, Lacey SF, Melenhorst JJ, June CH, Gill S. A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor positive cells. Blood. PMID 31703119 DOI: 10.1182/Blood.2019001859 |
0.606 |
|
| 2019 |
He Y, Schreiber K, Wolf SP, Wen F, Steentoft C, Zerweck J, Steiner M, Sharma P, Shepard HM, Posey A, June CH, Mandel U, Clausen H, Leisegang M, Meredith SC, et al. Multiple cancer-specific antigens are targeted by a chimeric antibody receptor on a single cancer cell. Jci Insight. 4. PMID 31672936 DOI: 10.1172/Jci.Insight.130416 |
0.504 |
|
| 2019 |
Garfall AL, Dancy EK, Cohen AD, Hwang WT, Fraietta JA, Davis MM, Levine BL, Siegel DL, Stadtmauer EA, Vogl DT, Waxman A, Rapoport AP, Milone MC, June CH, Melenhorst JJ. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood Advances. 3: 2812-2815. PMID 31575532 DOI: 10.1182/Bloodadvances.2019000600 |
0.552 |
|
| 2019 |
Chong EA, Levine BL, Grupp SA, Davis MM, Siegel DL, Maude SL, Gladney WL, Frey NV, Porter DL, Hwang WT, Chong ER, June CH, Schuster SJ. CAR T cell viability release testing and clinical outcomes: is there a lower limit? Blood. PMID 31554634 DOI: 10.1182/Blood.2019002258 |
0.419 |
|
| 2019 |
Aghajanian H, Kimura T, Rurik JG, Hancock AS, Leibowitz MS, Li L, Scholler J, Monslow J, Lo A, Han W, Wang T, Bedi K, Morley MP, Linares Saldana RA, Bolar NA, ... ... June CH, et al. Targeting cardiac fibrosis with engineered T cells. Nature. PMID 31511695 DOI: 10.1038/S41586-019-1546-Z |
0.387 |
|
| 2019 |
Haas AR, Tanyi JL, O'Hara MH, Gladney WL, Lacey SF, Torigian DA, Soulen MC, Tian L, McGarvey M, Nelson AM, Farabaugh CS, Moon E, Levine BL, Melenhorst JJ, Plesa G, ... June CH, et al. Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 31420241 DOI: 10.1016/J.Ymthe.2019.07.015 |
0.498 |
|
| 2019 |
Benci JL, Johnson LR, Choa R, Xu Y, Qiu J, Zhou Z, Xu B, Ye D, Nathanson KL, June CH, Wherry EJ, Zhang NR, Ishwaran H, Hellmann MD, Wolchok JD, et al. Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade. Cell. 178: 933-948.e14. PMID 31398344 DOI: 10.1016/J.Cell.2019.07.019 |
0.454 |
|
| 2019 |
Singh N, June CH. Boosting engineered T cells. Science (New York, N.Y.). 365: 119-120. PMID 31296754 DOI: 10.1126/Science.Aax6331 |
0.487 |
|
| 2019 |
van Bruggen JAC, Martens AWJ, Fraietta JA, Hofland T, Tonino SH, Eldering E, Levin MD, Siska PJ, Endstra S, Rathmell JC, June CH, Porter DL, Melenhorst JJ, Kater AP, van der Windt GJW. Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T cell efficacy. Blood. PMID 31076448 DOI: 10.1182/Blood.2018885863 |
0.592 |
|
| 2019 |
Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, Vogl DT, Weiss BM, Dengel K, Nelson A, Plesa G, Chen F, Davis MM, Hwang WT, Young RM, ... ... June CH, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. The Journal of Clinical Investigation. 130. PMID 30896447 DOI: 10.1172/Jci126397 |
0.564 |
|
| 2019 |
Stein AM, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, Boyer MW, August KJ, Levine BL, Tomassian L, Shah S, Leung M, Huang PH, Awasthi R, Mueller KT, Wood PA, ... June CH, et al. Tisagenlecleucel Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T Cells. Cpt: Pharmacometrics & Systems Pharmacology. PMID 30848084 DOI: 10.1002/psp4.12388 |
0.451 |
|
| 2019 |
Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, ... ... June CH, et al. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. Jci Insight. 4. PMID 30830874 DOI: 10.1172/jci.insight.127684 |
0.656 |
|
| 2019 |
Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nature Reviews. Drug Discovery. PMID 30622344 DOI: 10.1038/S41573-018-0006-Z |
0.347 |
|
| 2019 |
Narayan V, Gladney W, Plesa G, Vapiwala N, Carpenter E, Maude SL, Lal P, Lacey SF, Melenhorst JJ, Sebro R, Farwell M, Hwang W, Moniak M, Gilmore J, Lledo L, ... ... June CH, et al. A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer. Journal of Clinical Oncology. 37: TPS347-TPS347. DOI: 10.1200/Jco.2020.38.6_Suppl.Tps269 |
0.561 |
|
| 2019 |
Garfall AL, Cohen AD, Lacey SF, Tian L, Hwang W, Vogl DT, Waxman A, Lancaster E, Nelson AM, Ferthio R, Fesnak A, Lamontagne A, Brennan A, Guilliams J, Gladney WL, ... ... June CH, et al. Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma Blood. 134: 1863-1863. DOI: 10.1182/Blood-2019-131515 |
0.437 |
|
| 2019 |
Chong EA, Gerson JN, Landsburg DJ, Nasta SD, Svoboda J, Porter DL, Dengel K, Siegel DL, Gilmore J, Barta SK, Levine BL, June CH, Schuster SJ. Outcomes in Aggressive B-Cell Non-Hodgkin Lymphomas with Anti-CD19 CAR T-Cell (CTL019) Products Not Meeting Commercial Release Specifications Blood. 134: 594-594. DOI: 10.1182/Blood-2019-131078 |
0.538 |
|
| 2019 |
Singh N, Frey NV, Engels B, Barrett DM, Shestova O, Ravikumar P, Shyu A, Highfill S, Zhao L, Peng L, Granda B, Ramones M, Lu XM, Christian DA, Perazzelli J, ... ... June CH, et al. Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy Blood. 134: 247-247. DOI: 10.1182/Blood-2019-131024 |
0.573 |
|
| 2019 |
Wang M, Pruteanu I, Cohen AD, Garfall AL, Milone MC, Tian L, Gonzalez VE, Gill S, Frey NV, Barrett DM, Ruella M, Lacey SF, Svoboda J, Chong EA, Fraietta JA, ... ... June CH, et al. Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors Blood. 134: 622-622. DOI: 10.1182/Blood-2019-122513 |
0.516 |
|
| 2019 |
Wang M, Pruteanu I, Cohen AD, Garfall AL, Tian L, Lacey SF, Fraietta JA, Brogdon J, Davis M, Gonzalez VE, Levine BL, Siegel DL, Milone MC, Stadtmauer EA, June CH, et al. Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma Blood. 134: 1909-1909. DOI: 10.1182/Blood-2019-122396 |
0.614 |
|
| 2019 |
Collins M, Kong W, Jung I, Wang M, Lundh SM, June CH, Melenhorst JJ. A Failure to Start: Aborted Activation of CAR T Cells in Chronic Lymphocytic Leukemia Blood. 134: 681-681. DOI: 10.1182/Blood-2019-122063 |
0.644 |
|
| 2019 |
Alanio C, Bengsch B, Gies JR, Henrickson S, Weng NP, Ritz-Romeo JA, O'Hara M, Melenhorst JJ, Lacey S, Young RM, June CH, Wherry EJ. Abstract A123: Skewed CD4 and CD8 T-cell differentiation in pancreatic cancer patients Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A123 |
0.588 |
|
| 2019 |
Uribe-Herranz M, Bittinger K, Rafail S, Pierini S, Guedan S, Bushman F, June C, Facciabene A. Abstract 4961: Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12 Cancer Research. 79: 4961-4961. DOI: 10.1158/1538-7445.Am2019-4961 |
0.481 |
|
| 2019 |
Chong E, Schuster S, Grupp S, Davis M, Siegel D, Maude S, Gladney W, Frey N, Porter D, June C, Levine B. Impact of CAR T-cell product viability on B-cell lymphoid malignancy outcomes Cytotherapy. 21: S19. DOI: 10.1016/J.Jcyt.2019.03.316 |
0.439 |
|
| 2019 |
Chen F, Fraietta JA, June CH, Xu Z, Joseph Melenhorst J, Lacey SF. Engineered T Cell Therapies from a Drug Development Viewpoint Engineering. 5: 140-149. DOI: 10.1016/J.Eng.2018.11.010 |
0.516 |
|
| 2019 |
Chong E, Svoboda J, Nasta S, Landsburg D, Winchell N, Chong E, Porter D, Levine B, June C, Schuster S. CD19-DIRECTED CAR T CELL THERAPY (CTL019) FOR RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL AND FOLLICULAR LYMPHOMAS: FOUR YEAR OUTCOMES Hematological Oncology. 37: 137-138. DOI: 10.1002/Hon.96_2629 |
0.528 |
|
| 2019 |
June C. NEXT GENERATION CAR T CELLS FOR LYMPHOMA AND BEYOND Hematological Oncology. 37: 34-34. DOI: 10.1002/Hon.2629 |
0.543 |
|
| 2018 |
Guedan S, Ruella M, June CH. Emerging Cellular Therapies for Cancer. Annual Review of Immunology. PMID 30526160 DOI: 10.1146/Annurev-Immunol-042718-041407 |
0.515 |
|
| 2018 |
Boyiadzis MM, Dhodapkar MV, Brentjens RJ, Kochenderfer JN, Neelapu SS, Maus MV, Porter DL, Maloney DG, Grupp SA, Mackall CL, June CH, Bishop MR. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. Journal For Immunotherapy of Cancer. 6: 137. PMID 30514386 DOI: 10.1186/S40425-018-0460-5 |
0.682 |
|
| 2018 |
Wang S, O'Rourke DM, Chawla S, Verma G, Nasrallah MP, Morrissette JJD, Plesa G, June CH, Brem S, Maloney E, Desai A, Wolf RL, Poptani H, Mohan S. Multiparametric magnetic resonance imaging in the assessment of anti-EGFRvIII chimeric antigen receptor T cell therapy in patients with recurrent glioblastoma. British Journal of Cancer. PMID 30478409 DOI: 10.1038/S41416-018-0342-0 |
0.441 |
|
| 2018 |
Choi BD, Maus MV, June CH, Sampson JH. ----Immunotherapy for Glioblastoma: Adoptive T-cell Strategies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30446589 DOI: 10.1158/1078-0432.Ccr-18-1625 |
0.727 |
|
| 2018 |
Watanabe K, Kuramitsu S, Posey AD, June CH. Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology. Frontiers in Immunology. 9: 2486. PMID 30416506 DOI: 10.3389/Fimmu.2018.02486 |
0.528 |
|
| 2018 |
Shah NN, Nagle SJ, Torigian DA, Farwell MD, Hwang WT, Frey N, Nasta SD, Landsburg D, Mato A, June CH, Schuster SJ, Porter DL, Svoboda J. Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas. Cytotherapy. PMID 30385043 DOI: 10.1016/J.Jcyt.2018.10.003 |
0.367 |
|
| 2018 |
Alcantara M, Tesio M, June CH, Houot R. CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells. Leukemia. PMID 30315238 DOI: 10.1038/S41375-018-0285-8 |
0.603 |
|
| 2018 |
Yin Y, Boesteanu AC, Binder ZA, Xu C, Reid RA, Rodriguez JL, Cook DR, Thokala R, Blouch K, McGettigan-Croce B, Zhang L, Konradt C, Cogdill AP, Panjwani MK, Jiang S, ... ... June CH, et al. Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas. Molecular Therapy Oncolytics. 11: 20-38. PMID 30306125 DOI: 10.1016/J.Omto.2018.08.002 |
0.471 |
|
| 2018 |
Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, Klichinsky M, Shestova O, Patel PR, Kulikovskaya I, Nazimuddin F, Bhoj VG, Orlando EJ, Fry TJ, Bitter H, ... ... June CH, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nature Medicine. PMID 30275568 DOI: 10.1038/S41591-018-0201-9 |
0.868 |
|
| 2018 |
Mueller KT, Waldron ER, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, Boyer MW, August K, Hamilton J, Awasthi R, Stein AM, Sickert D, Chakraborty A, Levine BL, June CH, et al. Clinical Pharmacology of Tisagenlecleucel in B-Cell Acute Lymphoblastic Leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30190371 DOI: 10.1158/1078-0432.Ccr-18-0758 |
0.471 |
|
| 2018 |
Ghassemi S, Nunez-Cruz S, O'Connor RS, Fraietta JA, Patel PR, Scholler J, Barrett DM, Lundh SM, Davis MM, Bedoya F, Leferovich J, Lacey SF, Levine BL, Grupp SA, June CH, et al. Reducing Ex Vivo Culture Improves the Anti-leukemic Activity of Chimeric Antigen Receptor (CAR)-T Cells. Cancer Immunology Research. PMID 30030295 DOI: 10.1158/2326-6066.Cir-17-0405 |
0.606 |
|
| 2018 |
June CH, Sadelain M. Chimeric Antigen Receptor Therapy. The New England Journal of Medicine. 379: 64-73. PMID 29972754 DOI: 10.1056/Nejmra1706169 |
0.538 |
|
| 2018 |
Svoboda J, Rheingold SR, Gill SI, Grupp SA, Lacey SF, Kulikovskaya I, Suhoski MM, Melenhorst JJ, Loudon B, Mato AR, Nasta SD, Landsburg DJ, Youngman MR, Levine BL, Porter DL, ... June CH, et al. Non-viral RNA chimeric antigen receptor modified T cells in patients with Hodgkin lymphoma. Blood. PMID 29925499 DOI: 10.1182/Blood-2018-03-837609 |
0.842 |
|
| 2018 |
Castellarin M, Watanabe K, June CH, Kloss CC, Posey AD. Driving cars to the clinic for solid tumors. Gene Therapy. PMID 29880908 DOI: 10.1038/S41434-018-0007-X |
0.476 |
|
| 2018 |
Fraietta JA, Nobles CL, Sammons MA, Lundh S, Carty SA, Reich TJ, Cogdill AP, Morrissette JJD, DeNizio JE, Reddy S, Hwang Y, Gohil M, Kulikovskaya I, Nazimuddin F, Gupta M, ... ... June CH, et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature. PMID 29849141 DOI: 10.1038/S41586-018-0178-Z |
0.871 |
|
| 2018 |
Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, Maus MV, Fraietta JA, Zhao Y, June CH. Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 29807781 DOI: 10.1016/J.Ymthe.2018.05.003 |
0.622 |
|
| 2018 |
Ruella M, June CH. Predicting Dangerous Rides in CAR T Cells: Bridging the Gap between Mice and Humans. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 29784587 DOI: 10.1016/J.Ymthe.2018.05.005 |
0.435 |
|
| 2018 |
Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu AC, Wang Y, O'Connor RS, Hwang WT, Pequignot E, Ambrose DE, Zhang C, Wilcox N, Bedoya F, ... ... June CH, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nature Medicine. PMID 29713085 DOI: 10.1038/S41591-018-0010-1 |
0.838 |
|
| 2018 |
O'Connor RS, Guo L, Ghassemi S, Snyder NW, Worth AJ, Weng L, Kam Y, Philipson B, Trefely S, Nunez-Cruz S, Blair IA, June CH, Milone MC. The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations. Scientific Reports. 8: 6289. PMID 29674640 DOI: 10.1038/S41598-018-24676-6 |
0.421 |
|
| 2018 |
Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, ... ... June CH, et al. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. Jci Insight. 3. PMID 29669947 DOI: 10.1172/Jci.Insight.120505 |
0.741 |
|
| 2018 |
Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R, Baumgartner P, Stevenson BJ, Iseli C, Dangaj D, Czerniecki B, Semilietof A, Racle J, Michel A, Xenarios I, ... ... June CH, et al. Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Science Translational Medicine. 10. PMID 29643231 DOI: 10.1126/Scitranslmed.Aao5931 |
0.435 |
|
| 2018 |
Watanabe K, Luo Y, Da T, Guedan S, Ruella M, Scholler J, Keith B, Young RM, Engels B, Sorsa S, Siurala M, Havunen R, Tähtinen S, Hemminki A, June CH. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. Jci Insight. 3. PMID 29618658 DOI: 10.1172/Jci.Insight.99573 |
0.542 |
|
| 2018 |
Wing A, Fajardo CA, Posey AD, Shaw C, Da T, Young R, Alemany R, June CH, Guedan S. Improving CAR-T cell Therapy of solid tumors with Oncolytic Virus-driven Production of a Bispecific T-cell Engager. Cancer Immunology Research. PMID 29588319 DOI: 10.1158/2326-6066.Cir-17-0314 |
0.558 |
|
| 2018 |
June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science (New York, N.Y.). 359: 1361-1365. PMID 29567707 DOI: 10.1126/Science.Aar6711 |
0.548 |
|
| 2018 |
Beatty GL, O'Hara MH, Lacey SF, Torigian DA, Nazimuddin F, Chen F, Kulikovskaya IM, Soulen MC, McGarvey M, Nelson AM, Gladney WL, Levine BL, Melenhorst JJ, Plesa G, June CH. Activity of Mesothelin-specific Chimeric Antigen Receptor T cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. Gastroenterology. PMID 29567081 DOI: 10.1053/J.Gastro.2018.03.029 |
0.531 |
|
| 2018 |
Bagley SJ, Desai AS, Linette GP, June CH, O'Rourke DM. CAR T Cell Therapy for Glioblastoma: Recent Clinical Advances and Future Challenges. Neuro-Oncology. PMID 29509936 DOI: 10.1093/Neuonc/Noy032 |
0.584 |
|
| 2018 |
Uribe-Herranz M, Bittinger K, Rafail S, Guedan S, Pierini S, Tanes C, Ganetsky A, Morgan MA, Gill S, Tanyi JL, Bushman FD, June CH, Facciabene A. Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12. Jci Insight. 3. PMID 29467322 DOI: 10.1172/Jci.Insight.94952 |
0.479 |
|
| 2018 |
Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, ... ... June CH, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. The New England Journal of Medicine. 378: 439-448. PMID 29385370 DOI: 10.1056/Nejmoa1709866 |
0.435 |
|
| 2018 |
Steentoft C, Migliorini D, King TR, Mandel U, June CH, Posey AD. GLYCAN-DIRECTED CAR-T CELLS. Glycobiology. PMID 29370379 DOI: 10.1093/Glycob/Cwy008 |
0.571 |
|
| 2018 |
Guedan S, Posey AD, Shaw C, Wing A, Da T, Patel PR, McGettigan SE, Casado-Medrano V, Kawalekar OU, Uribe-Herranz M, Song D, Melenhorst JJ, Lacey SF, Scholler J, Keith B, ... ... June CH, et al. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. Jci Insight. 3. PMID 29321369 DOI: 10.1172/Jci.Insight.96976 |
0.633 |
|
| 2018 |
Cohen AD, Melenhorst JJ, Garfall AL, Lacey SF, Davis M, Vogl DT, Tian L, Gonzalez V, Pruteanu I, Nelson AM, Plesa G, Waxman A, Young RM, Levine BL, June CH, et al. Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Refractory Multiple Myeloma (MM) Blood. 132: 1974-1974. DOI: 10.1182/Blood-2018-99-119665 |
0.582 |
|
| 2018 |
Bernabei L, Garfall AL, Melenhorst JJ, Lacey SF, Stadtmauer EA, Vogl DT, Gonzalez V, Plesa G, Young RM, Waxman A, Levine BL, June CH, Milone MC, Cohen AD. PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells Blood. 132: 1973-1973. DOI: 10.1182/Blood-2018-99-119514 |
0.542 |
|
| 2018 |
Chong EA, Svoboda J, Dwivedy Nasta S, Landsburg DJ, Winchell N, Napier E, Mato AR, Melenhorst JJ, Ruella M, Lacey SF, June CH, Schuster SJ. Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas Blood. 132: 4198-4198. DOI: 10.1182/Blood-2018-99-119502 |
0.456 |
|
| 2018 |
Melenhorst JJ, Porter DL, Tian L, Lacey SF, Nobles CL, Fraietta JA, Frey NV, Kulikovskaya I, Gupta M, Young RM, Ambrose DE, Siegel DL, Bushman FD, June CH. Long-Term Remission of CLL Sustained By Pauciclonal Anti-CD19 Chimeric Antigen Receptor T (CTL019) Cell Clones Blood. 132: 699-699. DOI: 10.1182/Blood-2018-99-117390 |
0.649 |
|
| 2018 |
Singh N, Shestova O, Hayer K, Hong A, Ravikumar P, Hoshino A, Shalem O, Weitzman MD, June CH, Gill SI, Ruella M. CAR T Cell Cytotoxicity Is Dependent on Death Receptor-Driven Apoptosis Blood. 132: 698-698. DOI: 10.1182/Blood-2018-99-117328 |
0.474 |
|
| 2018 |
Nobles CL, Everett JK, Reddy S, Fraietta JA, Porter DL, Frey NV, Grupp SA, Siegel DL, Lacey SF, June CH, Bushman FD, Melenhorst JJ. Vector Integration and Efficacy of CD19-Directed CAR T Cell Therapy in Acute Lymphoblastic Leukemia (ALL) and Chronic Lymphocytic Leukemia (CLL) Blood. 132: 4548-4548. DOI: 10.1182/Blood-2018-99-117034 |
0.528 |
|
| 2018 |
Gill SI, Vides V, Frey NV, Metzger S, O'Brien M, Hexner E, Mato AR, Lacey SF, Melenhorst JJ, Pequignot E, Gladney WL, Hwang W, Lamontagne A, Davis M, Byrd JC, ... ... June CH, et al. Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate Blood. 132: 298-298. DOI: 10.1182/Blood-2018-99-115418 |
0.396 |
|
| 2018 |
Dancy E, Garfall AL, Cohen AD, Fraietta JA, Davis M, Levine BL, Siegel DL, Stadtmauer EA, Vogl DT, Waxman A, Rapoport AP, Milone MC, June CH, Melenhorst JJ. Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma Blood. 132: 1886-1886. DOI: 10.1182/Blood-2018-99-115319 |
0.604 |
|
| 2018 |
Li AM, Hucks GE, Dinofia AM, Seif AE, Teachey DT, Baniewicz D, Callahan C, Fasano C, McBride B, Gonzalez V, Nazimuddin F, Porter DL, Lacey SF, June CH, Grupp SA, et al. Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia Blood. 132: 556-556. DOI: 10.1182/Blood-2018-99-112572 |
0.603 |
|
| 2018 |
Chong EA, Levine BL, Grupp SA, Davis M, Siegel DL, Maude SL, Gladney WL, Frey NV, Porter DL, June CH, Schuster SJ. CD19-Directed CAR T-Cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodgkin Lymphomas and B-Cell Acute Lymphoblastic Leukemia Blood. 132: 197-197. DOI: 10.1182/Blood-2018-197 |
0.484 |
|
| 2018 |
June CH, Scholler J, Ruella M, Fraietta J, Melenhorst JJ, Ren J, Zhao Y. Abstract IA20: Updates on CAR T Cells Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-Ia20 |
0.63 |
|
| 2018 |
Uribe-Herranz M, Bittinger K, Rafail S, Guedan S, Pierini S, Tanes C, Gill SA, Tany J, Morgan MA, Bushman FD, June CH, Facciabene A. Abstract 3798: Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells Immunology. DOI: 10.1158/1538-7445.Am2018-3798 |
0.396 |
|
| 2017 |
Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, Wasik M, Levine BL, Lacey SF, Melenhorst JJ, Porter DL, ... June CH, et al. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. The New England Journal of Medicine. PMID 29226764 DOI: 10.1056/Nejmoa1708566 |
0.465 |
|
| 2017 |
Bailey SR, Nelson MH, Majchrzak K, Bowers JS, Wyatt MM, Smith AS, Neal LR, Shirai K, Carpenito C, June CH, Zilliox MJ, Paulos CM. Human CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence. Nature Communications. 8: 1961. PMID 29213079 DOI: 10.1038/S41467-017-01867-9 |
0.638 |
|
| 2017 |
Marcucci KT, Jadlowsky JK, Hwang WT, Suhoski-Davis M, Gonzalez VE, Kulikovskaya I, Gupta M, Lacey SF, Plesa G, Chew A, Melenhorst JJ, Levine BL, June CH. Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 29203150 DOI: 10.1016/J.Ymthe.2017.10.012 |
0.439 |
|
| 2017 |
Migliorini D, Dietrich PY, Stupp R, Linette GP, Posey AD, June CH. CAR-T cell Therapies in Glioblastoma: a first look. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29158268 DOI: 10.1158/1078-0432.Ccr-17-2871 |
0.512 |
|
| 2017 |
Tchou J, Zhao Y, Levine BL, Zhang PJ, Davis MM, Melenhorst JJ, Kulikovskaya I, Brennan AL, Liu X, Lacey SF, Posey A, Williams AD, So A, Conejo-Garcia JR, Plesa G, ... ... June CH, et al. Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer. Cancer Immunology Research. PMID 29109077 DOI: 10.1158/2326-6066.Cir-17-0189 |
0.495 |
|
| 2017 |
Obstfeld AE, Frey NV, Mansfield K, Lacey SF, June CH, Porter DL, Melenhorst JJ, Wasik MA. Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy; clinicopathological insights. Blood. PMID 29074500 DOI: 10.1182/Blood-2017-08-802413 |
0.525 |
|
| 2017 |
Singh N, Shi J, June CH, Ruella M. Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer. Current Hematologic Malignancy Reports. PMID 29039115 DOI: 10.1007/S11899-017-0417-7 |
0.444 |
|
| 2017 |
Cornetta K, Duffy L, Turtle CJ, Jensen M, Forman S, Binder-Scholl G, Fry T, Chew A, Maloney DG, June CH. Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 28970045 DOI: 10.1016/J.Ymthe.2017.09.008 |
0.422 |
|
| 2017 |
Hu B, Ren J, Luo Y, Keith B, Young RM, Scholler J, Zhao Y, June CH. Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18. Cell Reports. 20: 3025-3033. PMID 28954221 DOI: 10.1016/J.Celrep.2017.09.002 |
0.554 |
|
| 2017 |
Mueller KT, Maude SL, Porter DL, Frey N, Wood P, Han X, Waldron E, Chakraborty A, Awasthi R, Levine BL, Melenhorst JJ, Grupp SA, June CH, Lacey SF. Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood. PMID 28935694 DOI: 10.1182/Blood-2017-06-786129 |
0.477 |
|
| 2017 |
Kenderian SS, June CH, Gill S. Generating and Expanding Autologous Chimeric Antigen Receptor T Cells from Patients with Acute Myeloid Leukemia. Methods in Molecular Biology (Clifton, N.J.). 1633: 267-276. PMID 28735493 DOI: 10.1007/978-1-4939-7142-8_17 |
0.58 |
|
| 2017 |
O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot JM, ... ... June CH, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Science Translational Medicine. 9. PMID 28724573 DOI: 10.1126/Scitranslmed.Aaa0984 |
0.706 |
|
| 2017 |
Long M, Beckwith K, Do P, Mundy BL, Gordon A, Lehman AM, Maddocks KJ, Cheney C, Jones JA, Flynn JM, Andritsos LA, Awan F, Fraietta JA, June CH, Maus MV, et al. Ibrutinib treatment improves T cell number and function in CLL patients. The Journal of Clinical Investigation. PMID 28714866 DOI: 10.1172/Jci89756 |
0.638 |
|
| 2017 |
Sampson JH, Maus MV, June CH. Immunotherapy for Brain Tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017728089. PMID 28640704 DOI: 10.1200/Jco.2017.72.8089 |
0.535 |
|
| 2017 |
Ruella M, Klichinsky M, Kenderian SS, Shestova O, Ziober A, Kraft DO, Feldman M, Wasik MA, June CH, Gill S. Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. Cancer Discovery. PMID 28576927 DOI: 10.1182/Blood.V128.22.43.43 |
0.618 |
|
| 2017 |
Liu X, Jiang S, Fang C, Li H, Zhang X, Zhang F, June CH, Zhao Y. Novel T cells with improved in vivo anti-tumor activity generated by RNA electroporation. Protein & Cell. PMID 28523432 DOI: 10.1007/S13238-017-0422-6 |
0.594 |
|
| 2017 |
June CH, Warshauer JT, Bluestone JA. Is autoimmunity the Achilles' heel of cancer immunotherapy? Nature Medicine. 23: 540-547. PMID 28475571 DOI: 10.1038/Nm.4321 |
0.311 |
|
| 2017 |
Hippen KL, O'Connor RS, Lemire AM, Saha A, Hanse EA, Tennis NC, Merkel SC, Kelekar A, Riley JL, Levine BL, June CH, Kean LS, MacMillan ML, Miller JS, Wagner JE, et al. In vitro induction of human regulatory T-cells (iTregs) using conditions of low tryptophan plus kynurenines. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. PMID 28470889 DOI: 10.1182/Blood.V128.22.1229.1229 |
0.512 |
|
| 2017 |
Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, Lin AA, Schlom J, June CH, Sherwin SA. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. Journal For Immunotherapy of Cancer. 5: 22. PMID 28344808 DOI: 10.1186/S40425-017-0222-9 |
0.539 |
|
| 2017 |
Kawalekar O, June CH, Milone MC. Studying Immunoreceptor Signaling in Human T Cells Using Electroporation of In Vitro Transcribed mRNA. Methods in Molecular Biology (Clifton, N.J.). 1584: 443-450. PMID 28255718 DOI: 10.1007/978-1-4939-6881-7_27 |
0.573 |
|
| 2017 |
Tasian SK, Kenderian SS, Shen F, Ruella M, Shestova O, Kozlowski M, Li Y, Schrank-Hacker A, Morrissette JJ, Carroll M, June CH, Grupp SA, Gill S. Optimized Depletion of Chimeric Antigen Receptor T-Cells in Murine Xenograft Models of Human Acute Myeloid Leukemia. Blood. PMID 28246194 DOI: 10.1182/Blood-2016-08-736041 |
0.645 |
|
| 2017 |
Tanyi JL, Stashwick C, Plesa G, Morgan MA, Porter D, Maus MV, June CH. Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T Cells. Journal of Immunotherapy (Hagerstown, Md. : 1997). PMID 28234665 DOI: 10.1097/Cji.0000000000000160 |
0.727 |
|
| 2017 |
Ren J, Zhang X, Liu X, Fang C, Jiang S, June CH, Zhao Y. A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget. PMID 28199983 DOI: 10.18632/Oncotarget.15218 |
0.557 |
|
| 2017 |
Lim WA, June CH. The Principles of Engineering Immune Cells to Treat Cancer. Cell. 168: 724-740. PMID 28187291 DOI: 10.1016/J.Cell.2017.01.016 |
0.508 |
|
| 2017 |
Fajardo CA, Guedan S, Rojas LA, Moreno R, Arias-Badia M, de Sostoa J, June CH, Alemany R. Oncolytic adenoviral delivery of an EGFR-targeting T cell engager improves antitumor efficacy. Cancer Research. PMID 28143835 DOI: 10.1158/0008-5472.Can-16-1708 |
0.572 |
|
| 2017 |
Yin Y, Boesteanu A, Xu C, Posey A, Cook D, Blouch K, McGettigan-Croce B, Mason N, June CH, Lin Z, Johnson LA. Combinatorial IL13Rα2 chimeric antigen receptor-T cells plus checkpoint blockade to treat solid tumors in murine and canine models. Journal of Clinical Oncology. 35: 152-152. DOI: 10.1200/Jco.2017.35.7_Suppl.152 |
0.535 |
|
| 2017 |
Orlando E, Leary R, Lacey SF, Fraietta J, Bedoya F, Ambrose D, Wilcox N, Maude SL, Frey NV, Levine BL, Grupp SA, Porter DL, Young R, Winckler W, Morrissey M, ... June CH, et al. Gene expression signatures of response to anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with CLL and ALL. Journal of Clinical Oncology. 35: 137-137. DOI: 10.1200/Jco.2017.35.7_Suppl.137 |
0.601 |
|
| 2017 |
Gill S, Frey NV, Hexner EO, Lacey SF, Melenhorst JJ, Byrd JC, Metzger S, Marcus T, Gladney W, Marcucci K, Hwang W, June CH, Porter DL. CD19 CAR-T cells combined with ibrutinib to induce complete remission in CLL. Journal of Clinical Oncology. 35: 7509-7509. DOI: 10.1200/Jco.2017.35.15_Suppl.7509 |
0.498 |
|
| 2017 |
Kim RH, Plesa G, Gladney W, Kulikovskaya I, Levine BL, Lacey SF, June CH, Melenhorst JJ, Beatty GL. Effect of chimeric antigen receptor (CAR) T cells on clonal expansion of endogenous non-CAR T cells in patients (pts) with advanced solid cancer. Journal of Clinical Oncology. 35: 3011-3011. DOI: 10.1200/Jco.2017.35.15_Suppl.3011 |
0.581 |
|
| 2017 |
Talekar MK, Maude SL, Hucks GE, Motley LS, Callahan C, White CM, Baniewicz D, Barrett DM, Rheingold SR, Lacey SF, Levine BL, Melenhorst JJ, Teachey DT, June CH, Grupp SA. Effect of chimeric antigen receptor-modified T (CAR-T) cells on responses in children with non-CNS extramedullary relapse of CD19+ acute lymphoblastic leukemia (ALL). Journal of Clinical Oncology. 35: 10507-10507. DOI: 10.1200/Jco.2017.35.15_Suppl.10507 |
0.549 |
|
| 2017 |
Maude SL, Hucks GE, Seif AE, Talekar MK, Teachey DT, Baniewicz D, Callahan C, Gonzalez V, Nazimuddin F, Gupta M, Frey NV, Porter DL, Levine BL, Melenhorst JJ, Lacey SF, ... June CH, et al. The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL). Journal of Clinical Oncology. 35: 103-103. DOI: 10.1200/Jco.2017.35.15_Suppl.103 |
0.593 |
|
| 2017 |
Ruella M, Maude SL, Engels B, Barrett DM, Frey N, Marcucci KT, Shestova O, Singh N, Perazzelli J, Christian DA, Haagen D, Lacey SF, Melenhorst JJ, Brogdon J, Young RM, ... ... June CH, et al. Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models Blood. 130: 807-807. DOI: 10.1182/Blood.V130.Suppl_1.807.807 |
0.554 |
|
| 2017 |
Cohen AD, Garfall AL, Stadtmauer EA, Lacey SF, Lancaster E, Vogl DT, Weiss BM, Ambrose DE, Nelson AM, Chen F, Plesa G, Kulikovskaya I, Gonzalez V, Gupta M, Young RM, ... ... June CH, et al. Safety and Efficacy of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with Cyclophosphamide Conditioning for Refractory Multiple Myeloma (MM) Blood. 130: 505-505. DOI: 10.1182/Blood.V130.Suppl_1.505.505 |
0.413 |
|
| 2017 |
Chong EA, Melenhorst JJ, Svoboda J, Nasta SD, Landsburg DJ, Mato AR, Tian L, Parakandi H, Lacey SF, June CH, Schuster SJ. Phase I/II Study of Pembrolizumab for Progressive Diffuse Large B Cell Lymphoma after Anti-CD19 Directed Chimeric Antigen Receptor Modified T Cell Therapy Blood. 130: 4121-4121. DOI: 10.1182/Blood.V130.Suppl_1.4121.4121 |
0.488 |
|
| 2017 |
Fraietta JA, Lacey SF, Orlando E, Pruteanu J, Gohil M, Wang Y, Boesteanu A, OConnor R, Ambrose DE, Hwang W, Wilcox N, Bedoya F, Dorfmeier C, Chen F, Parakandi H, ... ... June CH, et al. Identification of Functional Determinants of Response and Resistance to CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy of Chronic Lymphocytic Leukemia Blood. 130: 3181-3181. DOI: 10.1182/Blood.V130.Suppl_1.3181.3181 |
0.621 |
|
| 2017 |
Stein AM, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, Boyer MW, August KJ, Levine BL, June CH, Tomassian L, Shah S, Leung M, Huang P, Jolivet S, Awasthi R, et al. CTL019 Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor (CAR) T Cells to Characterize the Impact of Tocilizumab on Expansion and to Identify Correlates of Cytokine Release Syndrome Severity Blood. 130: 2561-2561. DOI: 10.1182/Blood.V130.Suppl_1.2561.2561 |
0.518 |
|
| 2017 |
Cummins KD, Frey N, Nelson AM, Schmidt A, Luger S, Isaacs RE, Lacey SF, Hexner E, Melenhorst JJ, June CH, Porter DL, Gill SI. Treating Relapsed / Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells Blood. 130: 1359-1359. DOI: 10.1182/Blood.V130.Suppl_1.1359.1359 |
0.562 |
|
| 2017 |
Maude SL, Hucks GE, Callahan C, Baniewicz D, Fasano C, Barker C, Rheingold SR, Aplenc R, Dinofia AM, Li A, Teachey DT, Barrett DM, Brogdon J, Young RM, Scholler J, ... ... June CH, et al. Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia Blood. 130: 1319-1319. DOI: 10.1182/Blood.V130.Suppl_1.1319.1319 |
0.572 |
|
| 2017 |
Mueller KT, Waldron E, Sickert D, Grupp SA, Maude SL, Levine JE, Laetsch TW, Pulsipher MA, Boyer MW, August KJ, Awasthi R, Levine BL, June CH, Taran T, Wood PA, et al. Impact of Humoral Immunogenicity (Anti-mCAR19 Antibodies) on CTL019 Cellular Kinetics, Efficacy, and Safety Blood. 130: 1281-1281. DOI: 10.1182/Blood.V130.Suppl_1.1281.1281 |
0.361 |
|
| 2017 |
Tchou J, Zhang P, Levine B, Zhao Y, Matro J, DeMichele A, Amy C, Schuchter L, Plesa G, Vonderheide R, June C. Abstract P6-10-08: Preliminary results of a first in human Phase 1 clinical trial to demonstrate safety and feasibility of chimeric antigen receptor T (CART) cells directed against c-Met in the treatment of breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P6-10-08 |
0.414 |
|
| 2017 |
O'Rourke DM, Chen F, Binder ZA, Kulikovskaya I, Gupta M, Finklestein J, Ambrose DE, Nasrallah MP, June CH, Lacey SF, Melenhorst JJ. Abstract LB-053: Next-generation sequencing of T-cell receptor-beta gene rearrangements reveals dramatic expansion of T-cell clonotypes after CART-EGFRvIII therapy for glioblastoma Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-053 |
0.507 |
|
| 2017 |
Klichinsky M, Ruella M, Shestova O, Kenderian SS, Kim MY, O'Connor R, Scholler J, June C, Gill S. Abstract 4575: Chimeric antigen receptor macrophages (CARMA) for adoptive cellular immunotherapy of solid tumors Cancer Research. 77: 4575-4575. DOI: 10.1158/1538-7445.Am2017-4575 |
0.491 |
|
| 2017 |
Moon E, Kim S, Jean NS, O'Brien S, Maceyko S, Sun J, June C, Albelda S. Abstract 3749: Genetic blockade of the protein tyrosine phosphatase SHP1 augments CAR T cell activity against PDL1 expressing solid tumors Cancer Research. 77: 3749-3749. DOI: 10.1158/1538-7445.Am2017-3749 |
0.596 |
|
| 2017 |
Davis M, Fesnak A, Leskowitz R, McKee J, Ohayon Y, Corl C, Malykhin A, Fraietta J, Joseph Melenhorst J, June C, Schuster S, Levine B. Predictors of manufacturing (MFG) success for chimeric antigen receptor (CAR) T cells in Non-Hodgkin Lymphoma (NHL) Cytotherapy. 19: S118-S119. DOI: 10.1016/J.Jcyt.2017.02.190 |
0.516 |
|
| 2017 |
Hucks G, Barrett D, Rheingold S, Aplenc R, Teachey D, Callahan C, Baniewicz D, White C, Talekar M, Shaw P, Brogdon J, Young R, Scholler J, Marcucci K, Chew A, ... ... June C, et al. Humanized chimeric antigen receptor (CAR)-modified T cells targeting CD19 induce remissions in children and young adults with relapsed/refractory lymphoblastic leukemia/lymphoma Cytotherapy. 19: S9-S10. DOI: 10.1016/J.Jcyt.2017.02.011 |
0.525 |
|
| 2017 |
Qazilbash M, Stadtmauer E, Baladandayuthapani V, Tross B, Honhar M, Cha S, Kim K, Rao S, Popescu M, Shah N, Bashir Q, Patel K, Shpall E, Weber D, Thomas S, ... ... June C, et al. Randomized Phase II Trial of Combination Idiotype Vaccine and Anti-CD3/Anti-CD28 Costimulated Autologous T Cells in Patients with Multiple Myeloma Post-Autotransplantation Clinical Lymphoma Myeloma and Leukemia. 17: e138-e139. DOI: 10.1016/J.Exphem.2017.06.140 |
0.494 |
|
| 2017 |
Qazilbash M, Stadtmauer E, Baladandayuthapani V, Tross B, Honhar M, Cha S, Kim K, Rao S, Popescu M, Shah N, Bashir Q, Patel K, Shpall E, Weber D, Thomas S, ... ... June C, et al. Randomized phase II trial of combination idiotype vaccine and anti-CD3/anti-CD28 costimulated autologous T cells in patients with multiple myeloma post-autotransplantation Experimental Hematology. 53: S70-S71. DOI: 10.1016/j.exphem.2017.06.140 |
0.394 |
|
| 2017 |
Kenderian SS, Ruella M, Shestova O, Klichinsky M, Kim M, Soderquist C, Bagg A, Singh R, Richardson C, Young R, June CH, Gill SI. Targeting CLEC12A with Chimeric Antigen Receptor T Cells Can Overcome the Chemotherapy Refractoriness of Leukemia Stem Cells Biology of Blood and Marrow Transplantation. 23: S247-S248. DOI: 10.1016/J.Bbmt.2016.12.413 |
0.539 |
|
| 2017 |
Kenderian SS, Ruella M, Shestova O, Kim M, Klichinsky M, Chen F, Kengle N, Lacey S, Melenhorst J, June CH, Gill SI. Ruxolitinib Prevents Cytokine Release Syndrome after Car T-Cell Therapy Without Impairing the Anti-Tumor Effect in a Xenograft Model Biology of Blood and Marrow Transplantation. 23: S19-S20. DOI: 10.1016/j.bbmt.2016.12.003 |
0.334 |
|
| 2016 |
Chong EA, Melenhorst JJ, Lacey SF, Ambrose DE, Gonzalez V, Levine B, June CH, Schuster SJ. PD-1 Blockade Modulates Chimeric Antigen Receptor (CAR) Modified T Cells and Induces Tumor Regression: Refueling the CAR. Blood. PMID 28031179 DOI: 10.1182/Blood-2016-09-738245 |
0.369 |
|
| 2016 |
Johnson LA, June CH. Driving gene-engineered T cell immunotherapy of cancer. Cell Research. PMID 28025979 DOI: 10.1038/Cr.2016.154 |
0.546 |
|
| 2016 |
June CH. Drugging the Undruggable Ras - Immunotherapy to the Rescue? The New England Journal of Medicine. 375: 2286-2289. PMID 27959676 DOI: 10.1056/Nejme1612215 |
0.322 |
|
| 2016 |
McKenna DH, Sumstad D, Kadidlo DM, Batdorf B, Lord CJ, Merkel SC, Koellner CM, Curtsinger JM, June CH, Riley JL, Levine BL, Miller JS, Brunstein CG, Wagner JE, Blazar BR, et al. Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials. Cytotherapy. PMID 27887864 DOI: 10.1016/J.Jcyt.2016.10.011 |
0.434 |
|
| 2016 |
Leslie GJ, Wang J, Richardson MW, Haggarty BS, Hua KL, Duong J, Secreto AJ, Jordon AP, Romano J, Kumar KE, DeClercq JJ, Gregory PD, June CH, Root MJ, Riley JL, et al. Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus. Plos Pathogens. 12: e1005983. PMID 27855210 DOI: 10.1371/Journal.Ppat.1005983 |
0.378 |
|
| 2016 |
Posey AD, Clausen H, June CH. Distinguishing Truncated and Normal MUC1 Glycoform Targeting from Tn-MUC1-Specific CAR T Cells: Specificity Is the Key to Safety. Immunity. 45: 947-948. PMID 27851918 DOI: 10.1016/J.Immuni.2016.10.015 |
0.407 |
|
| 2016 |
Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27815355 DOI: 10.1158/1078-0432.Ccr-16-1300 |
0.556 |
|
| 2016 |
Rubin CB, Elenitsas R, Taylor L, Lacey SF, Kulikovskaya I, Gupta M, Melenhorst JJ, Loren A, Frey N, June CH, Porter D, Rosenbach M. Evaluating the skin in patients undergoing chimeric antigen receptor modified T-cell therapy. Journal of the American Academy of Dermatology. 75: 1054-1057. PMID 27745631 DOI: 10.1016/J.Jaad.2016.06.062 |
0.48 |
|
| 2016 |
Ruella M, Kenderian SS, Shestova O, Klichinsky M, Melenhorst JJ, Wasik MA, Lacey SF, June CH, Gill S. Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells (CART) for B cell neoplasms. Leukemia. PMID 27677739 DOI: 10.1182/Blood.V128.22.2159.2159 |
0.539 |
|
| 2016 |
Fitzgerald JC, Weiss SL, Maude SL, Barrett DM, Lacey SF, Melenhorst JJ, Shaw P, Berg RA, June CH, Porter DL, Frey NV, Grupp SA, Teachey DT. Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. Critical Care Medicine. PMID 27632680 DOI: 10.1097/Ccm.0000000000002053 |
0.452 |
|
| 2016 |
Brooks S, Frey N, Porter D, June C, Lacey S, Bagg A. The cytological features of CAR(T) cells. British Journal of Haematology. PMID 27612286 DOI: 10.1111/Bjh.14286 |
0.506 |
|
| 2016 |
Ruella M, Barrett DM, Kenderian SS, Shestova O, Hofmann TJ, Perazzelli J, Klichinsky M, Aikawa V, Nazimuddin F, Kozlowski M, Scholler J, Lacey SF, Melenhorst JJ, Morrissette JJ, Christian DA, ... ... June CH, et al. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. The Journal of Clinical Investigation. PMID 27571406 DOI: 10.1172/Jci87366 |
0.521 |
|
| 2016 |
Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nature Reviews. Cancer. 16: 566-81. PMID 27550819 DOI: 10.1038/Nrc.2016.97 |
0.539 |
|
| 2016 |
Lu Y, Hippen KL, Lemire AL, Gu J, Wang W, Ni X, Ranganathan P, Levine BL, Riley JL, June CH, Turka LA, Munn DH, Garzon R, Lu L, Blazar BR. miR-146b antagomir treated human Tregs increase TRAF6-NFkB expression, suppressor function and GVHD inhibitory potency. Blood. PMID 27485827 DOI: 10.1182/Blood-2016-05-714535 |
0.354 |
|
| 2016 |
Ruella M, June CH. Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You. Current Hematologic Malignancy Reports. PMID 27475429 DOI: 10.1007/S11899-016-0336-Z |
0.62 |
|
| 2016 |
Zsiros E, Dangaj D, June CH, Kandalaft LE, Coukos G. Ovarian cancer chemokines may not be a significant barrier during whole tumor antigen dendritic-cell vaccine and adoptive T-cell immunotherapy. Oncoimmunology. 5: e1062210. PMID 27467909 DOI: 10.1080/2162402X.2015.1062210 |
0.584 |
|
| 2016 |
June CH. Remote Controlled CARs: Towards a Safer Therapy for Leukemia. Cancer Immunology Research. PMID 27339039 DOI: 10.1158/2326-6066.Cir-16-0132 |
0.514 |
|
| 2016 |
Posey AD, Schwab RD, Boesteanu AC, Steentoft C, Mandel U, Engels B, Stone JD, Madsen TD, Schreiber K, Haines KM, Cogdill AP, Chen TJ, Song D, Scholler J, Kranz DM, ... ... June CH, et al. Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. Immunity. 44: 1444-1454. PMID 27332733 DOI: 10.1016/J.Immuni.2016.05.014 |
0.553 |
|
| 2016 |
Liu X, Barrett DM, Jiang S, Fang C, Kalos M, Grupp SA, June CH, Zhao Y. Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice. Blood Cancer Journal. 6: e430. PMID 27258611 DOI: 10.1038/Bcj.2016.38 |
0.631 |
|
| 2016 |
Bhoj VG, Arhontoulis D, Wertheim G, Capobianchi J, Callahan CA, Ellebrecht CT, Obstfeld AE, Lacey SF, Melenhorst JJ, Nazimuddin F, Hwang WT, Maude SL, Wasik MA, Bagg A, Schuster S, ... ... June CH, et al. Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T cell therapy. Blood. PMID 27166358 DOI: 10.1182/Blood-2016-01-694356 |
0.509 |
|
| 2016 |
Maus MV, June CH. Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 22: 1875-84. PMID 27084741 DOI: 10.1158/1078-0432.Ccr-15-1433 |
0.766 |
|
| 2016 |
Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, Pequignot E, Gonzalez VE, Chen F, Finklestein J, Barrett DM, Weiss SL, Fitzgerald JC, Berg RA, Aplenc R, ... ... June CH, et al. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T cell Therapy for Acute Lymphoblastic Leukemia. Cancer Discovery. PMID 27076371 DOI: 10.1158/2159-8290.Cd-16-0040 |
0.423 |
|
| 2016 |
Chen F, Teachey DT, Pequignot E, Frey N, Porter D, Maude SL, Grupp SA, June CH, Melenhorst JJ, Lacey SF. Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. Journal of Immunological Methods. PMID 27049586 DOI: 10.1016/J.Jim.2016.03.005 |
0.322 |
|
| 2016 |
Liu X, Ranganathan R, Jiang S, Fang C, Sun J, Kim S, Newick K, Lo A, June CH, Zhao Y, Moon EK. A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. Cancer Research. 76: 1578-90. PMID 26979791 DOI: 10.1158/0008-5472.Can-15-2524 |
0.509 |
|
| 2016 |
Singh N, Kulikovskaya I, Barrett DM, Binder-Scholl G, Jakobsen B, Martinez D, Pawel B, June CH, Kalos MD, Grupp SA. T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma. Oncoimmunology. 5: e1040216. PMID 26942053 DOI: 10.1080/2162402X.2015.1040216 |
0.546 |
|
| 2016 |
Kawalekar OU, O'Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD, Patel PR, Guedan S, Scholler J, Keith B, Snyder N, Blair I, Milone MC, June CH. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. Immunity. 44: 380-390. PMID 26885860 DOI: 10.1016/J.Immuni.2016.01.021 |
0.604 |
|
| 2016 |
Hexner EO, Luger SM, Reshef R, Jeschke GR, Mangan JK, Frey NV, Frank DM, Richman LP, Vonderheide RH, Aqui NA, Rosenbach M, Zhang Y, Chew A, Loren AW, Stadtmauer EA, ... ... June CH, et al. Infusion of CD3/CD28 co-stimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment. American Journal of Hematology. PMID 26858124 DOI: 10.1002/Ajh.24303 |
0.514 |
|
| 2016 |
Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, Maus MV, Liu X, Nunez-Cruz S, Klichinsky M, Kawalekar OU, Lacey SF, Milone M, Mato AR, Schuster SJ, ... ... June CH, et al. The Addition of the BTK inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26819453 DOI: 10.1158/1078-0432.Ccr-15-1527 |
0.721 |
|
| 2016 |
Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, Lacey SF, Melenhorst JJ, McGettigan SE, Cook DR, Zhang C, Xu J, Do P, Hulitt J, Kudchodkar SB, ... ... June CH, et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. PMID 26813675 DOI: 10.1182/Blood-2015-11-679134 |
0.77 |
|
| 2016 |
Garfall AL, Stadtmauer EA, June CH. Chimeric Antigen Receptor T Cells in Myeloma. The New England Journal of Medicine. 374: 194. PMID 26760100 DOI: 10.1056/Nejmc1512760 |
0.541 |
|
| 2016 |
Gracias DT, Boesteanu AC, Fraietta JA, Hope JL, Carey AJ, Mueller YM, Kawalekar OU, Fike AJ, June CH, Katsikis PD. Phosphatidylinositol 3-Kinase p110δ Isoform Regulates CD8+ T Cell Responses during Acute Viral and Intracellular Bacterial Infections. Journal of Immunology (Baltimore, Md. : 1950). PMID 26740110 DOI: 10.4049/Jimmunol.1501890 |
0.566 |
|
| 2016 |
Schuster SJ, Svoboda J, Nasta S, Chong EA, Porter DL, Landsburg DJ, Mato AR, Bhoj VG, Milone M, Lacey SF, Strelec LE, Zhou AY, Melenhorst JJ, Chew A, Hasskarl J, ... ... June CH, et al. Recovery of humoral immunity in patients with durable complete responses following chimeric antigen receptor modified t cells directed against CD19 (CTL019). Journal of Clinical Oncology. 34: 7564-7564. DOI: 10.1200/Jco.2016.34.15_Suppl.7564 |
0.513 |
|
| 2016 |
Frey NV, Shaw PA, Hexner EO, Gill S, Marcucci K, Luger SM, Mangan JK, Grupp SA, Maude SL, Ericson S, Levine B, Lacey SF, Melenhorst JJ, June CH, Porter DL. Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL). Journal of Clinical Oncology. 34: 7002-7002. DOI: 10.1200/Jco.2016.34.15_Suppl.7002 |
0.479 |
|
| 2016 |
Tanyi JL, Haas AR, Beatty GL, Stashwick CJ, O'Hara MH, Morgan MA, Porter DL, Melenhorst JJ, Plesa G, Lacey SF, June CH. Anti-mesothelin chimeric antigen receptor T cells in patients with epithelial ovarian cancer. Journal of Clinical Oncology. 34: 5511-5511. DOI: 10.1200/Jco.2016.34.15_Suppl.5511 |
0.512 |
|
| 2016 |
Maude SL, Teachey DT, Rheingold SR, Shaw PA, Aplenc R, Barrett DM, Barker CS, Callahan C, Frey NV, Nazimuddin F, Lacey SF, Zheng Z, Levine B, Melenhorst JJ, Motley L, ... ... June CH, et al. Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL. Journal of Clinical Oncology. 34: 3011-3011. DOI: 10.1200/Jco.2016.34.15_Suppl.3011 |
0.58 |
|
| 2016 |
Porter DL, Frey NV, Melenhorst JJ, Hwang W, Lacey SF, Shaw PA, Chew A, Marcucci K, Gill S, Loren AW, Mato AR, Schuster SJ, Lledo L, McConville H, Gilmore J, ... ... June CH, et al. Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R/R) CLL. Journal of Clinical Oncology. 34: 3009-3009. DOI: 10.1200/Jco.2016.34.15_Suppl.3009 |
0.561 |
|
| 2016 |
Maude SL, Barrett DM, Rheingold SR, Aplenc R, Teachey DT, Callahan C, Shaw PA, Brogdon J, Young R, Scholler J, Marcucci K, Kulikovskaya I, Nazimuddin F, Zheng Z, Levine B, ... ... June CH, et al. Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children with relapsed ALL. Journal of Clinical Oncology. 34: 3007-3007. DOI: 10.1200/Jco.2016.34.15_Suppl.3007 |
0.558 |
|
| 2016 |
O'Rourke DM, Nasrallah M, Morrissette JJ, Melenhorst JJ, Lacey SF, Mansfield K, Martinez-Lage M, Desai AS, Brem S, Maloney E, Mohan S, Wang S, Verma G, Navenot J, Shen A, ... ... June CH, et al. Pilot study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma. Journal of Clinical Oncology. 34: 2067-2067. DOI: 10.1200/Jco.2016.34.15_Suppl.2067 |
0.681 |
|
| 2016 |
Garfall AL, Stadtmauer EA, Maus MV, Hwang W, Vogl DT, Cohen AD, Weiss BM, Porter DL, Frey N, Milone M, Mangan P, Krevvata M, Ayers E, Dengel K, Kerr ND, ... ... June CH, et al. Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma Blood. 128: 974-974. DOI: 10.1182/Blood.V128.22.974.974 |
0.673 |
|
| 2016 |
Kenderian SS, Ruella M, Shestova O, Klichinsky M, Kim MY, Soderquist C, Bagg A, Singh R, Richardson C, Young RM, June CH, Gill SI. Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor T Cells Blood. 128: 766-766. DOI: 10.1182/Blood.V128.22.766.766 |
0.521 |
|
| 2016 |
Kenderian SS, Ruella M, Shestova O, Kim MY, Klichinsky M, Chen F, Kengle N, Lacey SF, Melenhorst JJ, June CH, Gill SI. Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model Blood. 128: 652-652. DOI: 10.1182/Blood.V128.22.652.652 |
0.456 |
|
| 2016 |
Garfall AL, Lancaster E, Stadtmauer EA, Lacey SF, Dengel K, Ambrose DE, Chen F, Gupta M, Kulikovskaya I, Vogl DT, Plesa G, Weiss BM, Ferthio R, Richardson C, Melenhorst JJ, ... ... June CH, et al. Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide Blood. 128: 5702-5702. DOI: 10.1182/Blood.V128.22.5702.5702 |
0.434 |
|
| 2016 |
Fraietta JA, Lacey SF, Wilcox NS, Bedoya F, Chen F, Orlando E, Brogdon JL, Hwang W, Frey N, Young RM, Pequignot E, Ambrose DE, Levine BL, Bitter H, Porter DL, ... ... June CH, et al. Biomarkers of Response to Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Chronic Lymphocytic Leukemia Blood. 128: 57-57. DOI: 10.1182/Blood.V128.22.57.57 |
0.606 |
|
| 2016 |
Ghassemi S, Prachi P, Scholler J, Nunez-Cruz S, Barrett DM, Bedoya F, Fraietta JA, Lacey SF, Levine BL, Grupp SA, June CH, Milone MC, Melenhorst JJ. Minimally Ex Vivo Manipulated Gene-Modified T Cells Display Enhanced Tumor Control Blood. 128: 4549-4549. DOI: 10.1182/Blood.V128.22.4549.4549 |
0.59 |
|
| 2016 |
Watanabe K, Guedan S, Scholler J, McGettigan S, Luo Y, Tähtinen S, Parviainen S, Havunen R, Siurala M, Hemminki A, June CH. Oncolytic Adenovirus Expressing Cytokines Enhances Anti-Tumor Efficacy of Mesothelin-Redirected CAR-T Cells Blood. 128: 3360-3360. DOI: 10.1182/Blood.V128.22.3360.3360 |
0.536 |
|
| 2016 |
Long M, Beckwith KA, Do P, Bethany ML, Gordon G, Lehman AM, Maddocks KJ, Cheney C, Jones J, Andritsos LA, Awan FT, Fraietta JA, June CH, Maus MV, Woyach JA, et al. Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism Blood. 128: 3238-3238. DOI: 10.1182/Blood.V128.22.3238.3238 |
0.767 |
|
| 2016 |
Schuster SJ, Svoboda J, Nasta SD, Chong EA, Winchell N, Landsburg DJ, Porter DL, Mato AR, Strauser HT, Schrank-Hacker AM, Wasik MA, Lacey SF, Melenhorst JJ, Chew A, Hasskarl J, ... ... June CH, et al. Treatment with Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) Results in Durable Remissions in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphomas of Germinal Center and Non-Germinal Center Origin, Double Hit Diffuse Large B Cell Lymphomas, and Transformed Follicular to Diffuse Large B Cell Lymphomas Blood. 128: 3026-3026. DOI: 10.1182/Blood.V128.22.3026.3026 |
0.351 |
|
| 2016 |
Lacey SF, Shaw PA, Teachey DT, Weiss SL, Chen F, Gonzalez VE, Frey N, Porter DL, Maude SL, Grupp SA, Pequignot E, June CH, Melenhorst JJ. Biomarker Profiling Differentiates Sepsis from Cytokine Release Syndrome in Chimeric Antigen Receptor T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL) Blood. 128: 2812-2812. DOI: 10.1182/Blood.V128.22.2812.2812 |
0.378 |
|
| 2016 |
Lacey SF, Xu J, Ruella M, Barrett DM, Kulikovskaya I, Ambrose DE, Patel PR, Reich T, Scholler J, Nazimuddin F, Fraietta JA, Maude SL, Gill SI, Levine BL, Nobles CL, ... ... June CH, et al. Cars in Leukemia: Relapse with Antigen-Negative Leukemia Originating from a Single B Cell Expressing the Leukemia-Targeting CAR Blood. 128: 281-281. DOI: 10.1182/Blood.V128.22.281.281 |
0.847 |
|
| 2016 |
Maude SL, Pulsipher MA, Boyer MW, Grupp SA, Davies SM, Phillips CL, Verneris MR, August KJ, Schlis K, Driscoll TA, Mody R, Capitini CM, June CH, Levine BL, Wood PA, et al. Efficacy and Safety of CTL019 in the First US Phase II Multicenter Trial in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of an Interim Analysis Blood. 128: 2801-2801. DOI: 10.1182/Blood.V128.22.2801.2801 |
0.399 |
|
| 2016 |
Grupp SA, Laetsch TW, Buechner J, Bittencourt H, Maude SL, Verneris MR, Myers GD, Boyer MW, Rives S, De Moerloose B, Nemecek ER, Schlis K, Martin PL, Qayed M, Bader P, ... ... June CH, et al. Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Blood. 128: 221-221. DOI: 10.1182/Blood.V128.22.221.221 |
0.41 |
|
| 2016 |
Mueller KT, Chakraborty A, Wood PA, Awasthi R, Quintas-Cardama A, Han X, Maude SL, Grupp SA, Porter DL, Frey N, Marcucci KT, Levine BL, Melenhorst JJ, June CH, Lacey SF. Cellular Kinetics of Chimeric Antigen Receptor T Cells (CTL019) in Patients with Relapsed/Refractory CD19+ Leukemia Blood. 128: 220-220. DOI: 10.1182/Blood.V128.22.220.220 |
0.518 |
|
| 2016 |
Maude SL, Barrett DM, Rheingold SR, Aplenc R, Teachey DT, Callahan C, Baniewicz D, White C, Talekar MK, Shaw PA, Brogdon JL, Young RM, Scholler J, Marcucci KT, Levine BL, ... ... June CH, et al. Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia Blood. 128: 217-217. DOI: 10.1182/Blood.V128.22.217.217 |
0.603 |
|
| 2016 |
Ruella M, Kenderian SS, Shestova O, Klichinsky M, Melenhorst JJ, Wasik MA, Lacey SF, June CH, Gill SI. Kinase Inhibitor Ibrutinib Prevents Cytokine-Release Syndrome after Anti-CD19 Chimeric Antigen Receptor T Cells (CART) for B Cell Neoplasms Blood. 128: 2159-2159. DOI: 10.1182/blood.V128.22.2159.2159 |
0.4 |
|
| 2016 |
Hippen KL, MacMillan ML, Lemire A, Saha A, Hanse E, Lord C, Kelekar A, O'Connor RS, Riley JL, June CH, Kean L, Miller JS, Wagner JE, Munn DH, Blazar BR. In Vitro Induction of Human Regulatory T-Cells (iTregs) Using Conditions of Low Tryptophan Plus Kynurenines Blood. 128: 1229-1229. DOI: 10.1182/blood.v128.22.1229.1229 |
0.39 |
|
| 2016 |
Cohen AD, Garfall AL, Stadtmauer EA, Lacey SF, Lancaster E, Vogl DT, Dengel K, Ambrose DE, Chen F, Plesa G, Kulikovskaya I, Gonzalez VE, Gupta M, Young RM, Carey T, ... ... June CH, et al. B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) for Multiple Myeloma (MM): Initial Safety and Efficacy from a Phase I Study Blood. 128: 1147-1147. DOI: 10.1182/Blood.V128.22.1147.1147 |
0.473 |
|
| 2016 |
Chong EA, Svoboda J, Nasta SD, Porter DL, Winchell N, Landsburg DJ, Mato AR, Lacey SF, Melenhorst JJ, Chew A, Hasskarl J, Marcucci KT, Levine BL, June CH, Schuster SJ. Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Poor Prognosis, Relapsed or Refractory CD19+ Follicular Lymphoma: Prolonged Remissions Relative to Antecedent Therapy Blood. 128: 1100-1100. DOI: 10.1182/Blood.V128.22.1100.1100 |
0.411 |
|
| 2016 |
Kenderian SS, Ruella M, Shestova O, Klichinsky M, Kim M, Porter DL, June CH, Gill S. Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia Biology of Blood and Marrow Transplantation. 22: S19-S21. DOI: 10.1182/Blood.V126.23.852.852 |
0.589 |
|
| 2016 |
June C. Abstract IA13: Engineered T cells for cancer therapy Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-Ia13 |
0.622 |
|
| 2016 |
Cogdill AP, Boesteanu A, Xu C, Haines K, Scholler J, Fraietta J, Zhao Y, Liu X, Morrissette J, Levine B, Lacey S, Loew A, Singh R, Brogdon J, O'Rourke DM, ... ... June CH, et al. Abstract B139: Toxicity testing of EGFRvIII CAR-based immunotherapy of glioblastoma: From bench to bedside Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-B139 |
0.739 |
|
| 2016 |
O’Rourke DM, Nasrallah MP, Morrissette J, Melenhorst JJ, Lacey SF, Mansfield K, Martinez-Lage M, Desai A, Brem S, Maloney E, Mohan S, Wang S, Verma G, Navenot J, Shen A, ... ... June CH, et al. Abstract LB-083: Phase I study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-083 |
0.725 |
|
| 2016 |
Singh N, Kulikovskaya I, Barrett DM, Binder-Scholl G, Jakobsen B, Martinez D, Pawel B, June CH, Kalos MD, Grupp SA. T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma Oncoimmunology. 5. DOI: 10.1080/2162402X.2015.1040216 |
0.434 |
|
| 2016 |
Kloss C, Lee J, June C. 638. TGFBeta Signaling Blockade within PSMA Targeted CAR Human T Cells for the Eradication of Metastatic Prostate Cancer Molecular Therapy. 24: S252-S253. DOI: 10.1016/S1525-0016(16)33446-3 |
0.581 |
|
| 2016 |
Watanabe K, Scholler J, Guedan S, McGettigan SE, Luo Y, Tähtinen S, Parviainen S, Havunen R, Siurala M, Hemminki A, June CH. 515. Oncolytic Adenovirus Armed with Cytokines Enhances CAR-T Cell Efficacy in Pancreatic Tumor Model Molecular Therapy. 24: S205-S206. DOI: 10.1016/S1525-0016(16)33324-X |
0.52 |
|
| 2016 |
Posey AD, Boestaneau A, Johnson LA, June CH. 510. Treating Epithelial and Metastatic Malignancies with Glycoform-Specific Chimeric Antigen Receptors Molecular Therapy. 24: S203-S204. DOI: 10.1016/S1525-0016(16)33319-6 |
0.493 |
|
| 2016 |
Ghassemi S, Bedoya F, Nunez-Cruz S, June C, Melenhorst J, Milone M. 203. Shortened T Cell Culture with IL-7 and IL-15 Provides the Most Potent Chimeric Antigen Receptor (CAR)-Modified T Cells for Adoptive Immunotherapy Molecular Therapy. 24: S79. DOI: 10.1016/S1525-0016(16)33012-X |
0.558 |
|
| 2016 |
Levine B, Maude S, Zheng Z, Shaw P, Ambrose D, Aplenc R, Barker C, Barrett D, Brogdon J, Callahan C, Chen F, Chew A, Suhoski Davis M, Fesnak A, Finklestein J, ... ... June C, et al. Durable Remissions with Control of Cytokine Release Syndrome (CRS) Using T Cells Expressing CD19 Targeted Chimeric Antigen Receptor (CAR) CTL019 to Treat Relapsed/Refractory (R/R) Acute Lymphoid Leukemia (ALL) Cytotherapy. 18: S14-S15. DOI: 10.1016/J.Jcyt.2016.03.039 |
0.477 |
|
| 2016 |
Halverson D, Rowley S, Bishop MR, Hansen B, Cotton S, Schuver BB, Steinberg SM, Hakim FT, Gea-Banacloche J, Hardy N, Sportes C, Pavletic SZ, Khuu H, Stroncek DF, Levine BL, ... June CH, et al. Preemptive T-Rapa Cell DLI after Low Intensity Allogeneic HCT May Allow for Improved Overall Survival in High Risk Lymphoid Malignancies Biology of Blood and Marrow Transplantation. 22: S139-S140. DOI: 10.1016/J.Bbmt.2015.11.478 |
0.438 |
|
| 2015 |
Brunstein CG, Miller JS, McKenna DH, Hippen KL, DeFor TE, Sumstad D, Curtsinger J, Verneris MR, MacMillan ML, Levine BL, Riley JI, June CH, Le C, Weisdorf D, McGlave PB, et al. Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile and clinical effect. Blood. PMID 26563133 DOI: 10.1182/Blood-2015-06-653667 |
0.507 |
|
| 2015 |
June CH, Levine BL. T cell engineering as therapy for cancer and HIV: our synthetic future. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 370. PMID 26416683 DOI: 10.1098/Rstb.2014.0374 |
0.476 |
|
| 2015 |
Garfall AL, Maus MV, Hwang WT, Lacey SF, Mahnke YD, Melenhorst JJ, Zheng Z, Vogl DT, Cohen AD, Weiss BM, Dengel K, Kerr ND, Bagg A, Levine BL, June CH, et al. Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. The New England Journal of Medicine. 373: 1040-7. PMID 26352815 DOI: 10.1056/Nejmoa1504542 |
0.718 |
|
| 2015 |
Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, Bagg A, Marcucci KT, Shen A, Gonzalez V, Ambrose D, Grupp SA, Chew A, Zheng Z, Milone MC, ... ... June CH, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science Translational Medicine. 7: 303ra139. PMID 26333935 DOI: 10.1126/Scitranslmed.Aac5415 |
0.59 |
|
| 2015 |
Liu X, Jiang S, Fang C, Yang S, Olalere D, Pequignot EC, Cogdill AP, Li N, Ramones M, Granda B, Zhou L, Loew A, Young RM, June CH, Zhao Y. Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. Cancer Research. 75: 3596-607. PMID 26330166 DOI: 10.1158/0008-5472.Can-15-0159 |
0.536 |
|
| 2015 |
Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J, Kulikovskaya I, Sinha SK, Kronsberg S, Gupta M, Bond S, ... ... June CH, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nature Medicine. 21: 914-21. PMID 26193344 DOI: 10.1038/Nm.3910 |
0.58 |
|
| 2015 |
Barrett DM, Grupp SA, June CH. Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street. Journal of Immunology (Baltimore, Md. : 1950). 195: 755-61. PMID 26188068 DOI: 10.4049/Jimmunol.1500751 |
0.594 |
|
| 2015 |
Fowler DH, Mossoba ME, Halverson DC, Kurlander R, Blacklock Schuver B, Carpenter AE, Hansen B, Steinberg SM, Ali SA, Tageja N, Hakim FT, Gea-Banacloche JC, Sportes C, Hardy NM, Hickstein DD, ... ... June CH, et al. High-Dose Sirolimus And Immune Selective Pentostatin Plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-Versus-Tumor Responses. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26071480 DOI: 10.1158/1078-0432.Ccr-15-0340 |
0.478 |
|
| 2015 |
Lo A, Wang LC, Scholler J, Monslow J, Avery D, Newick K, O'Brien S, Evans RA, Bajor DJ, Clendenin C, Durham AC, Buza EL, Vonderheide RH, June CH, Albelda SM, et al. Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells. Cancer Research. 75: 2800-10. PMID 25979873 DOI: 10.1158/0008-5472.Can-14-3041 |
0.479 |
|
| 2015 |
June CH. Serial Killers and Mass Murderers: Engineered T Cells Are up to the Task. Cancer Immunology Research. 3: 470-2. PMID 25941357 DOI: 10.1158/2326-6066.Cir-15-0075 |
0.328 |
|
| 2015 |
June CH, Riddell SR, Schumacher TN. Adoptive cellular therapy: a race to the finish line. Science Translational Medicine. 7: 280ps7. PMID 25810311 DOI: 10.1126/Scitranslmed.Aaa3643 |
0.535 |
|
| 2015 |
Kenderian SS, Ruella M, Shestova O, Klichinsky M, Aikawa V, Morrissette JJ, Scholler J, Song D, Porter DL, Carroll M, June CH, Gill S. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia. PMID 25721896 DOI: 10.1038/Leu.2015.52 |
0.587 |
|
| 2015 |
Zsiros E, Duttagupta P, Dangaj D, Li H, Frank R, Garrabrant T, Hagemann IS, Levine BL, June CH, Zhang L, Wang E, Marincola FM, Bedognetti D, Powell DJ, Tanyi J, et al. The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2840-50. PMID 25712684 DOI: 10.1158/1078-0432.Ccr-14-2777 |
0.568 |
|
| 2015 |
Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGettigan SE, Nace AK, Dentchev T, Thekkat P, Loew A, Boesteanu AC, Cogdill AP, Chen T, Fraietta JA, Kloss CC, ... ... June CH, et al. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Science Translational Medicine. 7: 275ra22. PMID 25696001 DOI: 10.1126/Scitranslmed.Aaa4963 |
0.717 |
|
| 2015 |
Frigault MJ, Lee J, Basil MC, Carpenito C, Motohashi S, Scholler J, Kawalekar OU, Guedan S, McGettigan SE, Posey AD, Ang S, Cooper LJ, Platt JM, Johnson FB, Paulos CM, ... ... June CH, et al. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunology Research. 3: 356-67. PMID 25600436 DOI: 10.1158/2326-6066.Cir-14-0186 |
0.62 |
|
| 2015 |
Gill S, June CH. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunological Reviews. 263: 68-89. PMID 25510272 DOI: 10.1111/Imr.12243 |
0.618 |
|
| 2015 |
Garfall AL, Maus MV, Lacey SF, Mahnke YD, Melenhorst JJ, Zheng Z, Vogl DT, Cohen AD, Weiss BM, Dengel K, Kerr ND, Hwang W, Levine B, June CH, Stadtmauer EA. Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR)-modified autologous T cells (CTL019) in advanced multiple myeloma. Journal of Clinical Oncology. 33: 8517-8517. DOI: 10.1200/Jco.2015.33.15_Suppl.8517 |
0.7 |
|
| 2015 |
Shah NN, Torigian DA, Farwell M, Hwang W, Frey NV, Nasta S, Landsburg DJ, Mato AR, June CH, Schuster SJ, Porter DL, Svoboda J. Utility of FDG-PET/CT in lymphoma patients undergoing immunotherapy with autologous CTL019 T-cells. Journal of Clinical Oncology. 33: 3022-3022. DOI: 10.1200/Jco.2015.33.15_Suppl.3022 |
0.344 |
|
| 2015 |
Beatty GL, O'Hara MH, Nelson AM, McGarvey M, Torigian DA, Lacey SF, Melenhorst JJ, Levine B, Plesa G, June CH. Safety and antitumor activity of chimeric antigen receptor modified T cells in patients with chemotherapy refractory metastatic pancreatic cancer. Journal of Clinical Oncology. 33: 3007-3007. DOI: 10.1200/Jco.2015.33.15_Suppl.3007 |
0.573 |
|
| 2015 |
Ruella M, Barrett DM, Kenderian SS, Shestova O, Hofmann TJ, Scholler J, Lacey SF, Melenhorst JJ, Nazimuddin F, Perazzelli J, Christian DA, Hunter CA, Porter DL, June CH, Grupp SA, et al. Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-O5 |
0.532 |
|
| 2015 |
Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, Maus MV, Liu X, Nunez-Cruz S, Klichinsky M, Kawalekar OU, Milone MC, Lacey SF, Mato A, Schuster SJ, ... ... June CH, et al. The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Engraftment and Antitumor Responses Against Mantle Cell Lymphoma Blood. 126: 704-704. DOI: 10.1182/Blood.V126.23.704.704 |
0.668 |
|
| 2015 |
Maude SL, Barrett DM, Ambrose DE, Rheingold SR, Aplenc R, Teachey DT, Callahan C, Barker CS, Mudambi M, Shaw PA, Brogdon J, Young RM, Scholler J, Loew A, Marcucci KT, ... ... June CH, et al. Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL Blood. 126: 683-683. DOI: 10.1182/Blood.V126.23.683.683 |
0.585 |
|
| 2015 |
Grupp SA, Maude SL, Shaw PA, Aplenc R, Barrett DM, Callahan C, Lacey SF, Levine BL, Melenhorst JJ, Motley L, Rheingold SR, Teachey DT, Wood PA, Porter D, June CH. Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019) Blood. 126: 681-681. DOI: 10.1182/Blood.V126.23.681.681 |
0.536 |
|
| 2015 |
Tasian SK, Kenderian SS, Shen F, Li Y, Ruella M, Fix WC, Kozlowski M, Carroll M, Aplenc R, June CH, Grupp SA, Gill SI. Efficient Termination of CD123-Redirected Chimeric Antigen Receptor T Cells for Acute Myeloid Leukemia to Mitigate Toxicity Blood. 126: 565-565. DOI: 10.1182/Blood.V126.23.565.565 |
0.645 |
|
| 2015 |
Castellarin M, Fraietta JA, Lee J, Scholler J, Zhao Y, June CH. A Novel Small Animal Model to Test on-Target Off-Tumor Cytoxicity of Adoptive Immune Therapies Blood. 126: 5432-5432. DOI: 10.1182/Blood.V126.23.5432.5432 |
0.551 |
|
| 2015 |
Liu X, Barrett DM, Jiang S, Fang C, Grupp SA, June CH, Zhao Y. Improved Anti-Leukemia Activities of Adoptively Transferred T Cells Expressing Bites Blood. 126: 4431-4431. DOI: 10.1182/Blood.V126.23.4431.4431 |
0.625 |
|
| 2015 |
Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Multiplex Cripsr/Cas9 Genome Editing to Generate Potent Universal CART and PD1-Deficient Cells Against Leukemia Blood. 126: 4280-4280. DOI: 10.1182/Blood.V126.23.4280.4280 |
0.623 |
|
| 2015 |
Rheingold SR, Chen LN, Maude SL, Aplenc R, Barker C, Barrett DM, Callahan C, Cebry K, Kulikovskaya I, Lacey SF, Levine BL, Melenhorst JJ, Shaw PA, Sparrow A, Teachey DT, ... ... June CH, et al. Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL Blood. 126: 3769-3769. DOI: 10.1182/Blood.V126.23.3769.3769 |
0.395 |
|
| 2015 |
Ruella M, Barrett DM, Kenderian SS, Shestova O, Hofmann TJ, Scholler J, Lacey SF, Melenhorst JJ, Nazimuddin F, Perazzelli J, Christian DA, Hunter CA, Porter DL, June CH, Grupp SA, et al. Combination of Anti-CD123 and Anti-CD19 Chimeric Antigen Receptor T Cells for the Treatment and Prevention of Antigen-Loss Relapses Occurring after CD19-Targeted Immunotherapies Blood. 126: 2523-2523. DOI: 10.1182/Blood.V126.23.2523.2523 |
0.549 |
|
| 2015 |
Schuster SJ, Svoboda J, Dwivedy Nasta S, Porter DL, Chong EA, Landsburg DJ, Mato AR, Lacey SF, Melenhorst JJ, Chew A, Hasskarl J, Shah GD, Wasik MA, Marcucci KT, Zheng Z, ... ... June CH, et al. Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas Blood. 126: 183-183. DOI: 10.1182/Blood.V126.23.183.183 |
0.425 |
|
| 2015 |
Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Frey NV, Maude SL, Barrett DM, Aplenc R, Chen F, Fitzgerald J, Gonzalez V, Pequignot E, Rheingold SR, Weiss S, White JC, ... June CH, et al. Biomarkers Accurately Predict Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Acute Lymphoblastic Leukemia (ALL) Blood. 126: 1334-1334. DOI: 10.1182/Blood.V126.23.1334.1334 |
0.448 |
|
| 2015 |
Schuster SJ, Svoboda J, Nasta S, Porter DL, Mato A, Shah GD, Landsburg DJ, Chong EA, Lacey SF, Melenhorst JJ, Chew A, Hasskarl J, Shah NN, Wasik MA, Marcucci K, ... ... June CH, et al. Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas. Journal of Clinical Oncology. 33: 8516-8516. DOI: 10.1182/Blood.V124.21.3087.3087 |
0.445 |
|
| 2015 |
Cogdill AP, Boesteanu A, Haines K, Fraietta J, Scholler J, Loew A, Thekkat P, Brogdon J, Maus MV, June C, Johnson LA. Abstract B05: A biologic screen to evaluate potential toxicity of chimeric antigen receptor modified T cells against primary normal human tissues Cancer Immunology Research. 3. DOI: 10.1158/2326-6074.Tumimm14-B05 |
0.716 |
|
| 2015 |
June CH, Porter D, Grupp S, Levine BL. Abstract IA10: CARs for leukemia and beyond? Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Hemmal14-Ia10 |
0.639 |
|
| 2015 |
Tanyi JL, Haas AR, Beatty GL, Morgan MA, Stashwick CJ, O'Hara MH, Porter DL, Maus MV, Levine BL, Lacey SF, Nelson AM, McGarvey M, Kerr ND, Plesa G, June CH. Abstract CT105: Safety and feasibility of chimeric antigen receptor modified T cells directed against mesothelin (CART-meso) in patients with mesothelin expressing cancers Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Ct105 |
0.709 |
|
| 2015 |
Moon EK, Ranganathan R, Liu X, Verona R, Snyder L, June CH, Zhao Y, Albelda SM. Abstract 4706: TCR engineered adoptive T-cell therapy for lung cancer is augmented by combined PD1 and TIM3 antibody blockade Cancer Research. 75: 4706-4706. DOI: 10.1158/1538-7445.Am2015-4706 |
0.566 |
|
| 2015 |
Rapoport A, Stadtmauer E, Melchiori L, Wong R, Davila E, Binder-Scholl G, Holdich T, Vogl D, Weiss B, Finkelstein J, Lacey S, Bond S, Fortin M, Peretz Y, Brewer J, ... ... June C, et al. Abstract 4701: NY-ESO T cells administered post ASCT for MM exhibit extended functionality without exhaustion in a natural pattern of effector and memory programming Cancer Research. 75: 4701-4701. DOI: 10.1158/1538-7445.Am2015-4701 |
0.573 |
|
| 2015 |
Lo A, Wang LS, Scholler J, Monslow J, Avery D, Evans RA, Bajor DJ, Durham AC, Buza EL, Vonderheide RH, June CH, Albelda SM, Puré E. Abstract 3187: Depleting cells expressing fibroblast activation protein disrupts tumor-promoting desmoplasia Immunology. 75: 3187-3187. DOI: 10.1158/1538-7445.Am2015-3187 |
0.355 |
|
| 2015 |
Kenderian SS, Ruella M, Shestova O, Klichinsky M, Scholler J, Song D, Porter DL, Carroll M, June CH, Gill S. Abstract 3139: CD33 directed chimeric antigen receptor T cell therapy as a novel regimen prior to allogeneic stem cell transplantation in acute myeloid leukemia Cancer Research. 75: 3139-3139. DOI: 10.1158/1538-7445.Am2015-3139 |
0.601 |
|
| 2015 |
June CH. Abstract KN01: Updates on engineered T cells as cancer therapies Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-Kn01 |
0.56 |
|
| 2015 |
O'Rourke D, Desai A, Morrissette J, Martinez-Lage M, Nasrallah M, Brem S, Maloney E, Shen A, Mohan S, Wang S, Verma G, Lacey S, Melenhorst J, Navenot J, Zheng Z, ... ... June C, et al. IMCT-15PILOT STUDY OF T CELLS REDIRECTED TO EGFRvIII WITH A CHIMERIC ANTIGEN RECEPTOR IN PATIENTS WITH EGFRvIII+ GLIOBLASTOMA Neuro-Oncology. 17: v110.4-v111. DOI: 10.1093/Neuonc/Nov218.15 |
0.698 |
|
| 2015 |
Guedan S, Patel P, McGettigan SE, Posey AD, Kawalekar O, Scholler J, Keith B, June CH. 719. Combination of ICOS and 4-1BB in a Third Generation CAR Exhibits Enhanced T Cell Persistence and Increased Antitumor Effect Molecular Therapy. 23: S287. DOI: 10.1016/S1525-0016(16)34328-3 |
0.635 |
|
| 2015 |
Kawalekar OU, O'Connor RS, Fraietta J, Guedan S, Scholler J, Milone MC, June CH. 516. Chimeric Antigen Receptors With Distinct Signaling Domains Can Reprogram T Cells Molecular Therapy. 23: S206-S207. DOI: 10.1016/S1525-0016(16)34125-9 |
0.564 |
|
| 2015 |
Posey AD, Schwab RD, Boestaneau A, Johnson LA, June CH. 515. Targeting Hypoglycosylation with a Chimeric Antigen Receptor Molecular Therapy. 23: S206. DOI: 10.1016/S1525-0016(16)34124-7 |
0.579 |
|
| 2015 |
Posey AD, June CH. 211. CD2, the First Identified T cell Co-Stimulator, Demonstrates More Effective Chimeric Antigen Receptor Activity Over CD28 and 4-1BB Molecular Therapy. 23: S83. DOI: 10.1016/S1525-0016(16)33816-3 |
0.628 |
|
| 2015 |
Levine B, Svoboda J, Nasta SD, Porter D, Chong E, Lacey S, Mahnke Y, Melenhorst J, Chew A, Shah G, Hasskar J, Wasik M, Landsburg D, Mato A, Garfall A, ... ... June C, et al. Chimeric antigen receptor modified T cells directed against CD19 (CTL019) induce clinical responses in patients with relapsed or refractory CD19+ lymphomas Cytotherapy. 17: S13. DOI: 10.1016/J.Jcyt.2015.03.327 |
0.571 |
|
| 2015 |
Brunstein C, Hippen K, Defor TE, McKenna D, Curtsinger J, Sumstad D, Levine BL, June CH, Miller JS, Verneris MR, Blazar BR, Wagner JE. Prevention of Acute GVHD by Ex Vivo Expanded Umbilical Cord Blood Derived Regulatory T Cells (Treg) Biology of Blood and Marrow Transplantation. 21: S55-S56. DOI: 10.1016/J.Bbmt.2014.11.054 |
0.464 |
|
| 2015 |
Kenderian SS, Ruella M, Shestova O, Klichinsky M, Scholler J, Song D, Porter DL, Carroll M, June CH, Gill S. CD33 Directed Chimeric Antigen Receptor T Cell Therapy As a Novel Preparative Regimen Prior to Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Biology of Blood and Marrow Transplantation. 21: S25-S26. DOI: 10.1016/J.Bbmt.2014.11.013 |
0.55 |
|
| 2014 |
Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGettigan SE, Nace A, Thekkat P, Loew A, Chen TJ, Fraietta JA, Posey AD, Boesteanu AC, Cogdill AP, Engels B, ... ... June C, et al. Pre-clinical validation of a humanized anti-EGFR variant III chimeric antigen receptor and phase I trial of CART-EGFRvIII in glioblastoma Journal For Immunotherapy of Cancer. 2: 1-1. PMID 25746013 DOI: 10.1186/2051-1426-2-S3-O1 |
0.677 |
|
| 2014 |
Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, ... ... June CH, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. The New England Journal of Medicine. 371: 1507-17. PMID 25317870 DOI: 10.1056/Nejmoa1407222 |
0.561 |
|
| 2014 |
June CH. Toward synthetic biology with engineered T cells: a long journey just begun. Human Gene Therapy. 25: 779-84. PMID 25244569 DOI: 10.1089/Hum.2014.2533 |
0.304 |
|
| 2014 |
Corrigan-Curay J, Kiem HP, Baltimore D, O'Reilly M, Brentjens RJ, Cooper L, Forman S, Gottschalk S, Greenberg P, Junghans R, Heslop H, Jensen M, Mackall C, June C, Press O, et al. T-cell immunotherapy: looking forward. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 1564-74. PMID 25186558 DOI: 10.1038/Mt.2014.148 |
0.513 |
|
| 2014 |
Singh N, Liu X, Hulitt J, Jiang S, June CH, Grupp SA, Barrett DM, Zhao Y. Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma. Cancer Immunology Research. 2: 1059-70. PMID 25104548 DOI: 10.1158/2326-6066.Cir-14-0051 |
0.542 |
|
| 2014 |
Guedan S, Chen X, Madar A, Carpenito C, McGettigan SE, Frigault MJ, Lee J, Posey AD, Scholler J, Scholler N, Bonneau R, June CH. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. Blood. 124: 1070-80. PMID 24986688 DOI: 10.1182/Blood-2013-10-535245 |
0.597 |
|
| 2014 |
June CH, Maus MV, Plesa G, Johnson LA, Zhao Y, Levine BL, Grupp SA, Porter DL. Engineered T cells for cancer therapy. Cancer Immunology, Immunotherapy : Cii. 63: 969-75. PMID 24943274 DOI: 10.1007/S00262-014-1568-1 |
0.645 |
|
| 2014 |
Maus MV, June CH. CARTs on the road for myeloma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3899-901. PMID 24919574 DOI: 10.1158/1078-0432.Ccr-14-0721 |
0.716 |
|
| 2014 |
Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, Kapoor V, Scholler J, Puré E, Milone MC, June CH, Riley JL, Wherry EJ, Albelda SM. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4262-73. PMID 24919573 DOI: 10.1158/1078-0432.Ccr-13-2627 |
0.522 |
|
| 2014 |
Wang LC, Lo A, Scholler J, Sun J, Majumdar RS, Kapoor V, Antzis M, Cotner CE, Johnson LA, Durham AC, Solomides CC, June CH, Puré E, Albelda SM. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunology Research. 2: 154-66. PMID 24778279 DOI: 10.1158/2326-6066.Cir-13-0027 |
0.61 |
|
| 2014 |
Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, Spratt SK, Surosky RT, Giedlin MA, Nichol G, Holmes MC, Gregory PD, Ando DG, Kalos M, Collman RG, ... ... June CH, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. The New England Journal of Medicine. 370: 901-10. PMID 24597865 DOI: 10.1056/Nejmoa1300662 |
0.589 |
|
| 2014 |
Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, Carroll M, Danet-Desnoyers G, Scholler J, Grupp SA, June CH, Kalos M. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood. 123: 2343-54. PMID 24596416 DOI: 10.1182/Blood-2013-09-529537 |
0.605 |
|
| 2014 |
Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, Kalos M, June CH. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunology Research. 2: 112-20. PMID 24579088 DOI: 10.1158/2326-6066.Cir-13-0170 |
0.72 |
|
| 2014 |
Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood. 123: 2625-35. PMID 24578504 DOI: 10.1182/Blood-2013-11-492231 |
0.703 |
|
| 2014 |
Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Xu YY, Kalos M, Cai L, Fang HB, Weiss BM, Badros A, Yanovich S, Akpek G, Tsao P, Cross A, Mann D, ... ... June CH, et al. Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1355-65. PMID 24520093 DOI: 10.1158/1078-0432.Ccr-13-2817 |
0.491 |
|
| 2014 |
Barrett DM, Singh N, Liu X, Jiang S, June CH, Grupp SA, Zhao Y. Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy. Cytotherapy. 16: 619-30. PMID 24439255 DOI: 10.1016/J.Jcyt.2013.10.013 |
0.475 |
|
| 2014 |
Maus MV, Fraietta JA, Levine BL, Kalos M, Zhao Y, June CH. Adoptive immunotherapy for cancer or viruses. Annual Review of Immunology. 32: 189-225. PMID 24423116 DOI: 10.1146/Annurev-Immunol-032713-120136 |
0.616 |
|
| 2014 |
Vonderheide RH, June CH. Engineering T cells for cancer: our synthetic future. Immunological Reviews. 257: 7-13. PMID 24329786 DOI: 10.1111/Imr.12143 |
0.572 |
|
| 2014 |
Barrett DM, Singh N, Porter DL, Grupp SA, June CH. Chimeric antigen receptor therapy for cancer. Annual Review of Medicine. 65: 333-47. PMID 24274181 DOI: 10.1146/Annurev-Med-060512-150254 |
0.459 |
|
| 2014 |
Didigu CA, Wilen CB, Wang J, Duong J, Secreto AJ, Danet-Desnoyers GA, Riley JL, Gregory PD, June CH, Holmes MC, Doms RW. Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection. Blood. 123: 61-9. PMID 24162716 DOI: 10.1182/Blood-2013-08-521229 |
0.418 |
|
| 2014 |
Guedan S, McGettigan SE, Posey AD, Lee J, Kawalekar O, Patel PR, Keith B, June C. Enhancing T cell persistence of CAR-redirected T cells in solid tumors Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P244 |
0.626 |
|
| 2014 |
Han C, Sim S, Kim KH, Lee DG, Oh HS, Park SH, Hwang S, Kim WY, Lee S, Kim YH, Choi BK, June C, Kwon BS. Selective killing of malignant B cells using T cells redirected against malignancy variant receptor Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P16 |
0.591 |
|
| 2014 |
Ruella M, Barrett D, Kenderian SS, Shestova O, Hofmann TJ, Scholler J, Lacey SF, Melenhorst JJ, Nazimuddin F, Kalos M, Porter DL, June CH, Grupp SA, Gill SI. Novel Chimeric Antigen Receptor T Cells for the Treatment of CD19-Negative Relapses Occurring after CD19-Targeted Immunotherapies Blood. 124: 966-966. DOI: 10.1182/Blood.V124.21.966.966 |
0.534 |
|
| 2014 |
Ruella M, Kenderian SS, Shestova O, Chen T, Scholler J, Wasik MA, June CH, Gill SI. Novel Chimeric Antigen Receptor T Cells for the Treatment of Hodgkin Lymphoma Blood. 124: 806-806. DOI: 10.1182/Blood.V124.21.806.806 |
0.647 |
|
| 2014 |
Kawalekar OU, O'Connor R, Guedan S, Fraietta J, Posey AD, Scholler J, Milone MC, June CH. Signaling Domain of Chimeric Antigen Receptors Can Reprogram T Cells Blood. 124: 551-551. DOI: 10.1182/Blood.V124.21.551.551 |
0.624 |
|
| 2014 |
Posey AD, Schwab RD, Boestaneau A, Johnson LA, June CH. Glycopeptide-Specific Chimeric Antigen Receptor Targeting of T Cell Leukemia Blood. 124: 4803-4803. DOI: 10.1182/Blood.V124.21.4803.4803 |
0.627 |
|
| 2014 |
Grupp SA, Maude SL, Shaw P, Aplenc R, Barrett DM, Callahan C, Chew A, Lacey SF, Levine BL, Melenhorst JJ, Motley L, Rheingold SR, Shen A, Teachey DT, Wood PA, ... ... June CH, et al. T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL Blood. 124: 380-380. DOI: 10.1182/Blood.V124.21.380.380 |
0.558 |
|
| 2014 |
Frey NV, Levine BL, Lacey SF, Grupp SA, Maude SL, Schuster SJ, Shaw P, Hwang W, Wasik MA, Obstfeld A, Leung M, Shen A, Ericson SG, Melenhorst JJ, June CH, et al. Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells Blood. 124: 2296-2296. DOI: 10.1182/Blood.V124.21.2296.2296 |
0.339 |
|
| 2014 |
Porter DL, Lacey SF, Hwang W, Shaw P, Frey NV, Chew A, Chen F, Kalos M, Gonzalez V, Marcucci KT, Maude SL, Melenhorst JJ, Litchman M, Teachey DT, Shen A, ... ... June CH, et al. Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL Blood. 124: 1983-1983. DOI: 10.1182/Blood.V124.21.1983.1983 |
0.323 |
|
| 2014 |
Porter DL, Frey NV, Melenhorst JJ, Hwang W, Lacey SF, Shaw P, Chew A, Grupp SA, Capobianchi J, Gilmore J, Kalos M, Litchman M, Lledo L, Loren AW, Mahnke Y, ... ... June CH, et al. Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL Blood. 124: 1982-1982. DOI: 10.1182/Blood.V124.21.1982.1982 |
0.42 |
|
| 2014 |
Bhoj V, Milone MC, June CH, Porter D, Grupp SA, Melenhorst JJ, Lacey SF, Callahan C, Capobianchi J, Wertheim G, Mahnke Y. Humoral Immunity and Plasma Cell Changes in Patients Responding to CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T-Cell Adoptive Immunotherapy Blood. 124: 1110-1110. DOI: 10.1182/Blood.V124.21.1110.1110 |
0.54 |
|
| 2014 |
Grupp SA, Maude S, Aplenc R, Barrett DM, Kalos M, Levine B, Lichtman M, Rheingold S, Shen A, Strait C, Teachey D, Wood PA, June C. Abstract PR06: T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce complete responses and long-term persistence without GVHD in children with relapsed, refractory ALL Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-Pr06 |
0.599 |
|
| 2014 |
Hassan NJ, Bossi G, Baker D, Adams K, Harper J, Dukes J, Liddy N, Paston S, McGrath Y, Mahon T, Molloy P, Sami M, Baston E, Cameron B, Johnson A, ... ... June C, et al. Abstract 2900: IMCgp100: A novel bi-specific biologic for the treatment of malignant melanoma Cancer Research. 74: 2900-2900. DOI: 10.1158/1538-7445.Am2014-2900 |
0.545 |
|
| 2014 |
Melenhorst JJ, Porter DL, Lacey SF, Loren AW, Jemison C, Gilmore J, McConville H, Capobianchi J, Lledo L, Chew A, Zheng Z, Levine BL, June CH. SP-024 CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELLS FOR RELAPSED, REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA Leukemia Research. 38: S12. DOI: 10.1016/S0145-2126(14)70026-8 |
0.487 |
|
| 2014 |
Ruella M, Shestova O, Kenderian S, Barrett D, Grupp S, Scholler J, Lacey S, Kalos M, June C, Gill S. Anti-CD123 chimeric antigen receptor redirected T cells for relapsed B-cell acute lymphoblastic leukemia Cytotherapy. 16: S8. DOI: 10.1016/J.Jcyt.2014.01.017 |
0.455 |
|
| 2014 |
Halverson D, Rowley S, Hansen B, Schuver BB, Mossoba M, Steinberg S, Hakim F, Kurlander R, Gea-Banacloche J, Sportes C, Hardy N, Hickstein D, Pavletic SZ, Khuu H, Castiello L, ... ... June CH, et al. T-Rapa6 and T-Rapa12 Cells Differentially Mediate Acute Gvhd after Low-Intensity Allogeneic HCT Biology of Blood and Marrow Transplantation. 20: S130-S131. DOI: 10.1016/J.Bbmt.2013.12.199 |
0.513 |
|
| 2013 |
Ohno M, Ohkuri T, Kosaka A, Tanahashi K, June CH, Natsume A, Okada H. Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts. Journal For Immunotherapy of Cancer. 1: 21. PMID 24829757 DOI: 10.1186/2051-1426-1-21 |
0.492 |
|
| 2013 |
Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunology Research. 1: 26-31. PMID 24777247 DOI: 10.1158/2326-6066.Cir-13-0006 |
0.711 |
|
| 2013 |
Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunology Research. 1: 26-31. PMID 24432303 |
0.677 |
|
| 2013 |
Lanitis E, Poussin M, Klattenhoff AW, Song D, Sandaltzopoulos R, June CH, Powell DJ. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunology Research. 1: 43-53. PMID 24409448 DOI: 10.1158/2326-6066.Cir-13-0008 |
0.607 |
|
| 2013 |
Tchou J, Zhang PJ, Bi Y, Satija C, Marjumdar R, Stephen TL, Lo A, Chen H, Mies C, June CH, Conejo-Garcia J, Puré E. Fibroblast activation protein expression by stromal cells and tumor-associated macrophages in human breast cancer. Human Pathology. 44: 2549-57. PMID 24074532 DOI: 10.1016/J.Humpath.2013.06.016 |
0.39 |
|
| 2013 |
Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, Grand F, Brewer JE, Gupta M, Plesa G, Bossi G, Vuidepot A, Powlesland AS, Legg A, Adams KJ, ... ... June CH, et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Science Translational Medicine. 5: 197ra103. PMID 23926201 DOI: 10.1126/Scitranslmed.3006034 |
0.437 |
|
| 2013 |
Kalos M, June CH. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity. 39: 49-60. PMID 23890063 DOI: 10.1016/J.Immuni.2013.07.002 |
0.503 |
|
| 2013 |
Barrett DM, Liu X, Jiang S, June CH, Grupp SA, Zhao Y. Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. Human Gene Therapy. 24: 717-27. PMID 23883116 DOI: 10.1089/Hum.2013.075 |
0.458 |
|
| 2013 |
Kalbasi A, June CH, Haas N, Vapiwala N. Radiation and immunotherapy: a synergistic combination. The Journal of Clinical Investigation. 123: 2756-63. PMID 23863633 DOI: 10.1172/Jci69219 |
0.302 |
|
| 2013 |
Levine BL, June CH. Perspective: assembly line immunotherapy. Nature. 498: S17. PMID 23803946 DOI: 10.1038/498S17A |
0.307 |
|
| 2013 |
Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ, Binder-Scholl GK, Smethurst DP, Gerry AB, Pumphrey NJ, Bennett AD, ... ... June CH, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 122: 863-71. PMID 23770775 DOI: 10.1182/Blood-2013-03-490565 |
0.722 |
|
| 2013 |
Kumar AJ, Hexner EO, Frey NV, Luger SM, Loren AW, Reshef R, Boyer J, Smith J, Stadtmauer EA, Levine BL, June CH, Porter DL, Goldstein SC. Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 19: 1094-101. PMID 23635453 DOI: 10.1016/J.Bbmt.2013.04.021 |
0.424 |
|
| 2013 |
Riese MJ, Wang LC, Moon EK, Joshi RP, Ranganathan A, June CH, Koretzky GA, Albelda SM. Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases. Cancer Research. 73: 3566-77. PMID 23576561 DOI: 10.1158/0008-5472.Can-12-3874 |
0.594 |
|
| 2013 |
Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. The New England Journal of Medicine. 368: 1509-18. PMID 23527958 DOI: 10.1056/Nejmoa1215134 |
0.635 |
|
| 2013 |
Kandalaft LE, Powell DJ, Chiang CL, Tanyi J, Kim S, Bosch M, Montone K, Mick R, Levine BL, Torigian DA, June CH, Coukos G. Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology. 2: e22664. PMID 23482679 DOI: 10.4161/Onci.22664 |
0.45 |
|
| 2013 |
Maus MV, June CH. Zoom Zoom: racing CARs for multiple myeloma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 1917-9. PMID 23444214 DOI: 10.1158/1078-0432.Ccr-13-0168 |
0.715 |
|
| 2013 |
Fowler DH, Mossoba ME, Steinberg SM, Halverson DC, Stroncek D, Khuu HM, Hakim FT, Castiello L, Sabatino M, Leitman SF, Mariotti J, Gea-Banacloche JC, Sportes C, Hardy NM, Hickstein DD, ... ... June CH, et al. Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation. Blood. 121: 2864-74. PMID 23426943 DOI: 10.1182/Blood-2012-08-446872 |
0.568 |
|
| 2013 |
Santegoets SJ, Turksma AW, Suhoski MM, Stam AG, Albelda SM, Hooijberg E, Scheper RJ, van den Eertwegh AJ, Gerritsen WR, Powell DJ, June CH, de Gruijl TD. IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells. Journal of Translational Medicine. 11: 37. PMID 23402380 DOI: 10.1186/1479-5876-11-37 |
0.829 |
|
| 2013 |
Maier DA, Brennan AL, Jiang S, Binder-Scholl GK, Lee G, Plesa G, Zheng Z, Cotte J, Carpenito C, Wood T, Spratt SK, Ando D, Gregory P, Holmes MC, Perez EE, ... ... June CH, et al. Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5. Human Gene Therapy. 24: 245-58. PMID 23360514 DOI: 10.1089/Hum.2012.172 |
0.551 |
|
| 2013 |
McGarrity GJ, Hoyah G, Winemiller A, Andre K, Stein D, Blick G, Greenberg RN, Kinder C, Zolopa A, Binder-Scholl G, Tebas P, June CH, Humeau LM, Rebello T. Patient monitoring and follow-up in lentiviral clinical trials. The Journal of Gene Medicine. 15: 78-82. PMID 23322669 DOI: 10.1002/Jgm.2691 |
0.317 |
|
| 2013 |
Tebas P, Stein D, Binder-Scholl G, Mukherjee R, Brady T, Rebello T, Humeau L, Kalos M, Papasavvas E, Montaner LJ, Schullery D, Shaheen F, Brennan AL, Zheng Z, Cotte J, ... ... June CH, et al. Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV. Blood. 121: 1524-33. PMID 23264589 DOI: 10.1182/Blood-2012-07-447250 |
0.551 |
|
| 2013 |
McCormack E, Adams KJ, Hassan NJ, Kotian A, Lissin NM, Sami M, Mujić M, Osdal T, Gjertsen BT, Baker D, Powlesland AS, Aleksic M, Vuidepot A, Morteau O, Sutton DH, ... June CH, et al. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Cancer Immunology, Immunotherapy : Cii. 62: 773-85. PMID 23263452 DOI: 10.1007/S00262-012-1384-4 |
0.457 |
|
| 2013 |
Riddell SR, Jensen MC, June CH. Chimeric antigen receptor--modified T cells: clinical translation in stem cell transplantation and beyond. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 19: S2-5. PMID 23085599 DOI: 10.1016/J.Bbmt.2012.10.021 |
0.549 |
|
| 2013 |
Kunii N, Zhao Y, Jiang S, Liu X, Scholler J, Balagopalan L, Samelson LE, Milone MC, June CH. Enhanced function of redirected human T cells expressing linker for activation of T cells that is resistant to ubiquitylation. Human Gene Therapy. 24: 27-37. PMID 22998346 DOI: 10.1089/Hum.2012.130 |
0.613 |
|
| 2013 |
Porter DL, Frey NV, Loren AW, Levine B, Kalos M, McConville H, Gilmore J, Chew A, Shen A, So C, Sharr M, Wood PA, June CH. A phase II, dose-optimization trial of autologous T cells genetically engineered to express anti-CD19 chimeric antigen receptor (CART-19) in patients with relapsed or refractory (r/r) CD19+ chronic lymphocytic leukemia (CLL). Journal of Clinical Oncology. 31: TPS7132-TPS7132. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps7132 |
0.565 |
|
| 2013 |
Grupp SA, Porter DL, Levine B, Kalos M, Strait C, Rheingold SR, Aplenc R, June CH. Pilot study of redirected autologous T cells engineered to contain anti-CD19 attached to TCRζ and 4-1BB signaling domains in patients with chemotherapy-resistant or -refractory CD19+ leukemia and lymphoma. Journal of Clinical Oncology. 31: TPS10072-TPS10072. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps10072 |
0.561 |
|
| 2013 |
Rapoport AP, Stadtmauer EA, Vogl DT, Weiss B, Binder-Scholl GK, Smethurst DP, Finklestein J, Kulikovskaya I, Gupta M, Brewer JE, Bennett AD, Gerry AB, Pumphrey NJ, Tayton-Martin HK, Ribeiro L, ... ... June CH, et al. Adoptive immunotherapy with engineered T cells expressing and HLA-A2 restricted affinity-enhanced TCR for LAGE-1 and NY-ESO-1 in patients with multiple myeloma following auto-SCT Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P30 |
0.473 |
|
| 2013 |
Rapoport AP, Stadtmauer EA, Vogl DT, Weiss BM, Binder-Scholl GK, Smethurst DP, Finklestein J, Kulikovskaya I, Gupta M, Brewer JE, Bennett AD, Gerry AB, Pumphrey NJ, Tayton-Martin HK, Ribeiro LC, ... ... June CH, et al. Engineered T-Cells Expressing An HLA-Restricted Affinity-Enhanced TCR In Advanced Multiple Myeloma Patients Post Auto-SCT Engraft and Are Associated With Encouraging Post Auto-SCT Responses Blood. 122: 766-766. DOI: 10.1182/Blood.V122.21.766.766 |
0.602 |
|
| 2013 |
Grupp SA, Frey NV, Aplenc R, Barrett DM, Chew A, Kalos M, Levine BL, Litchman M, Maude SL, Rheingold SR, Shen A, Strait C, Teachey DT, Wood PA, Porter D, ... June CH, et al. T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL Blood. 122: 67-67. DOI: 10.1182/Blood.V122.21.67.67 |
0.576 |
|
| 2013 |
Kalos M, Frey NV, Grupp SA, Loren AW, Jemison C, Gilmore J, McConville H, Capobianchi J, Lledo L, Chew A, Zheng Z, Levine BL, June CH. Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019 cells) Have Long-Term Persistence and Induce Durable Responses In Relapsed, Refractory CLL Blood. 122: 4162-4162. DOI: 10.1182/Blood.V122.21.4162.4162 |
0.592 |
|
| 2013 |
Kawalekar OU, Posey AD, Fraietta J, Lee J, Scholler J, Zhao Y, June CH. Distinct Signaling By Chimeric Antigen Receptors (CARs) Containing CD28 Signaling Domain Versus 4-1BB In Primary Human T Cells Blood. 122: 2902-2902. DOI: 10.1182/Blood.V122.21.2902.2902 |
0.63 |
|
| 2013 |
Kalos M, Nazimuddin F, Finklestein JM, Gupta M, Kulikovskaya I, Ambrose DE, Gill S, Lacey SF, Zheng Z, Melenhorst JJ, Levine BL, Frey NV, Grupp SA, Porter DL, June CH. Long-Term Functional Persistence, B Cell Aplasia and Anti-Leukemia Efficacy In Refractory B Cell Malignancies Following T Cell Immunotherapy Using CAR-Redirected T Cells Targeting CD19 Blood. 122: 163-163. DOI: 10.1182/Blood.V122.21.163.163 |
0.558 |
|
| 2013 |
Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, Carroll M, Danet-Desnoyers G, Scholler J, Grupp SA, June CH, Kalos M. Anti-CD123 Chimeric Antigen Receptor T Cells (CART-123) Provide A Novel Myeloablative Conditioning Regimen That Eradicates Human Acute Myeloid Leukemia In Preclinical Models Blood. 122: 143-143. DOI: 10.1182/Blood.V122.21.143.143 |
0.599 |
|
| 2013 |
Wang LS, Lo A, Scholler J, June CH, Pure E, Albelda SM. Abstract PR14: Fibroblast activation protein as a universal target for chimeric antigen receptor T cell therapy in solid tumors. Cancer Research. 73. DOI: 10.1158/1538-7445.Tumimm2012-Pr14 |
0.538 |
|
| 2013 |
June CH. Abstract IA16: Engineered T cell therapies for cancer. Cancer Research. 73. DOI: 10.1158/1538-7445.Tumimm2012-Ia16 |
0.593 |
|
| 2013 |
Rapoport AP, Stadtmauer EA, Vogl DT, Weiss B, Binder-Scholl GK, Smethurst DP, Finkelstein J, Kulikovskaya I, Gupta M, Suppa E, Mikheeva T, Brewer JE, Bennett AD, Gerry AB, Pumphrey NJ, ... ... June CH, et al. Abstract 4575: Correlates of clinical response following autologous stem cell transplant and adoptive immunotherapy with engineered T cells expressing an affinity-enhanced T cell receptor in patients with mutliple myeloma. Cancer Research. 73: 4575-4575. DOI: 10.1158/1538-7445.Am2013-4575 |
0.597 |
|
| 2013 |
Grupp SA, Kalos M, Barrett DM, Teachey DT, Levine B, Milone M, Porter D, June CH. Abstract 4574: Use of CD19-targeted Chimeric Antigen Receptor-modified T (CART19) cells in ALL and CLL produce transient cytokine release syndrome (CRS), macrophage activation syndrome (MAS) and durable responses. Cancer Research. 73: 4574-4574. DOI: 10.1158/1538-7445.Am2013-4574 |
0.544 |
|
| 2013 |
Barrett DM, Zhao Y, Liu X, Jiang S, Reid GSD, Seif AE, June CH, Grupp SA. Abstract 3972: Carpet bombing with CARs: Influence of dose, timing, lymphodepletion and costimulatory domain on efficacy of mRNA engineered anti-CD19 Chimeric Antigen Receptor T cells in preclinical xenograft models. Cancer Research. 73: 3972-3972. DOI: 10.1158/1538-7445.Am2013-3972 |
0.608 |
|
| 2013 |
Zsiros E, Lee H, Hagemann IS, Duttagupta P, Frank R, Garrabrant T, Levine BL, June CH, Tanyi J, Kandalaft L, Feldman M, Coukos G. Abstract 3968: Ovarian cancer chemokine microenvironment is conducive to homing of CD3/CD28 co-stimulated T cells prepared for adoptive transfer therapy. Cancer Research. 73: 3968-3968. DOI: 10.1158/1538-7445.Am2013-3968 |
0.584 |
|
| 2013 |
June CH. Abstract PL07-04: Engineered T cell transfer for cancer immunotherapy in the era of synthetic biology: Challenges and opportunities. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-Pl07-04 |
0.454 |
|
| 2013 |
Tebas P, June C, Stein D, Wang S, Lee G, Levine B, Tang W, Ando D. B107 Results of a phase 1 using CCR5 Deficiency with Zinc Finger Nuclease-modified Autologous CD4 T Cells (SB-728-T) in HIV-infected Subjects Jaids Journal of Acquired Immune Deficiency Syndromes. 62: S37. DOI: 10.1097/01.Qai.0000429208.01732.16 |
0.504 |
|
| 2013 |
Gill S, Tasian S, Scholler J, Porter D, Carroll M, Grupp S, June C, Kalos M. Effective targeting of primary human acute myeloid leukemia using anti-CD123 chimeric antigen receptor engineered T cells Cytotherapy. 15: S13-S14. DOI: 10.1016/J.Jcyt.2013.01.047 |
0.553 |
|
| 2013 |
Levine B, Rapoport A, Stadtmauer E, Vogl D, Weiss B, Binder-Scholl G, Smethurst D, Brewer J, Bennett A, Gerry A, Pumphrey N, Tayton-Martin H, Ribiero L, Veloso E, Finklestein J, ... ... June C, et al. Adoptive transfer of gene-modified T-cells engineered to express high-affinity tcr's for cancer-testis antigens NY-ESO-1 or lage-1, in multiple myeloma (MM) patients post autologous hematopoietic stem cell transplant (ASCT) Cytotherapy. 15: S13. DOI: 10.1016/J.Jcyt.2013.01.046 |
0.522 |
|
| 2013 |
Sportes C, Cole K, Siegel D, Rowley S, Halverson D, Hardy N, Pavletic SZ, Gea-Banacloche J, Mann J, Urban A, Fellowes V, Sabatino M, Stroncek DF, Levine B, Mossoba M, ... ... June CH, et al. Multi-Center Phase I Study of Th1/Tc1 Immunotherapy Following Autologous Hematopoietic Progenitor Cell Transplantation in Reccurrent or High Risk Plasma Cell Myeloma Biology of Blood and Marrow Transplantation. 19: S197-S198. DOI: 10.1016/J.Bbmt.2012.11.212 |
0.352 |
|
| 2013 |
Garfall AL, Kalos M, Furth EE, Vogl D, Weiss B, Cantor J, Gupta M, Levine B, Rapoport A, Ribeiro L, Jakobsen B, Smethurst D, Binder-Scholl G, June CH, Stadtmauer EA. Autologous aGVHD Associated with Infusion of T-Cells with Engineered Specificity for NY-ESO-1 and LAGE-1 Following High-Dose Melphalan and ASCT in Patients with Multiple Myeloma Biology of Blood and Marrow Transplantation. 19: S134. DOI: 10.1016/J.Bbmt.2012.11.071 |
0.458 |
|
| 2012 |
Grupp SA, Prak EL, Boyer J, McDonald KR, Shusterman S, Thompson E, Callahan C, Jawad AF, Levine BL, June CH, Sullivan KE. Adoptive transfer of autologous T cells improves T-cell repertoire diversity and long-term B-cell function in pediatric patients with neuroblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 6732-41. PMID 23092876 DOI: 10.1158/1078-0432.Ccr-12-1432 |
0.569 |
|
| 2012 |
Hoxie JA, June CH. Novel cell and gene therapies for HIV. Cold Spring Harbor Perspectives in Medicine. 2. PMID 23028130 DOI: 10.1101/Cshperspect.A007179 |
0.336 |
|
| 2012 |
June C, Rosenberg SA, Sadelain M, Weber JS. T-cell therapy at the threshold. Nature Biotechnology. 30: 611-4. PMID 22781680 DOI: 10.1038/Nbt.2305 |
0.533 |
|
| 2012 |
Liddy N, Bossi G, Adams KJ, Lissina A, Mahon TM, Hassan NJ, Gavarret J, Bianchi FC, Pumphrey NJ, Ladell K, Gostick E, Sewell AK, Lissin NM, Harwood NE, Molloy PE, ... ... June CH, et al. Monoclonal TCR-redirected tumor cell killing. Nature Medicine. 18: 980-7. PMID 22561687 DOI: 10.1038/Nm.2764 |
0.545 |
|
| 2012 |
Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, Vogel AN, Kalos M, Riley JL, Deeks SG, Mitsuyasu RT, Bernstein WB, Aronson NE, Levine BL, Bushman FD, ... June CH, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Science Translational Medicine. 4: 132ra53. PMID 22553251 DOI: 10.1126/Scitranslmed.3003761 |
0.623 |
|
| 2012 |
Tchou J, Wang LC, Selven B, Zhang H, Conejo-Garcia J, Borghaei H, Kalos M, Vondeheide RH, Albelda SM, June CH, Zhang PJ. Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Research and Treatment. 133: 799-804. PMID 22418702 DOI: 10.1007/S10549-012-2018-4 |
0.423 |
|
| 2012 |
June C, Levine B. Blocking HIV's attack. Scientific American. 306: 54-9. PMID 22375323 DOI: 10.1038/Scientificamerican0312-54 |
0.409 |
|
| 2012 |
Bear AS, Morgan RA, Cornetta K, June CH, Binder-Scholl G, Dudley ME, Feldman SA, Rosenberg SA, Shurtleff SA, Rooney CM, Heslop HE, Dotti G. Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 246-9. PMID 22297819 DOI: 10.1038/Mt.2011.288 |
0.538 |
|
| 2012 |
Hardy NM, Fellowes V, Rose JJ, Odom J, Pittaluga S, Steinberg SM, Blacklock-Schuver B, Avila DN, Memon S, Kurlander RJ, Khuu HM, Stetler-Stevenson M, Mena E, Dwyer AJ, Levine BL, ... June CH, et al. Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation. Blood. 119: 2956-9. PMID 22289893 DOI: 10.1182/Blood-2011-09-378398 |
0.518 |
|
| 2012 |
Chu CS, Boyer J, Schullery DS, Gimotty PA, Gamerman V, Bender J, Levine BL, Coukos G, Rubin SC, Morgan MA, Vonderheide RH, June CH. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunology, Immunotherapy : Cii. 61: 629-41. PMID 22021066 DOI: 10.1007/S00262-011-1081-8 |
0.343 |
|
| 2012 |
Kalos M, Levine BL, Macatee TL, Kulikovskaya I, Suppa E, Jena B, Gill SI, Cooper LJN, Grupp SA, Porter DL, June CH. Sustained Functional T Cell Persistence and B Cell Aplasia Following CD19-Targeting Adoptive T Cell Immunotherapy for Relapsed, Refractory CD19+ Malignacy Blood. 120: 756-756. DOI: 10.1182/Blood.V120.21.756.756 |
0.598 |
|
| 2012 |
Kalos M, Rapoport AP, Stadtmauer EA, Vogl DT, Weiss BM, Binder-Scholl GK, Smethurst DP, Kulikovskaya I, Gupta M, Macatee TL, Finklestein JM, Brewer JE, Bennett AD, Gerry AB, Pumphrey NJ, ... ... June CH, et al. Prolonged T Cell Persistence, Homing to Marrow and Selective Targeting of Antigen Positive Tumor in Multiple Myeloma Patients Following Adoptive Transfer of T Cells Genetically Engineered to Express an Affinity-Enhanced T Cell Receptor Against the Cancer Testis Antigens NY-ESO-1 and Lage-1 Blood. 120: 755-755. DOI: 10.1182/Blood.V120.21.755.755 |
0.605 |
|
| 2012 |
Porter DL, Grupp SA, Kalos M, Loren AW, Lledo L, Gilmore J, Milone MC, Chew A, Levine BL, June CH. Chimeric Antigen Receptor T Cells Directed Against CD19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL Blood. 120: 717-717. DOI: 10.1182/Blood.V120.21.717.717 |
0.509 |
|
| 2012 |
Rapoport AP, Stadtmauer EA, Vogl DT, Weiss BM, Binder-Scholl GK, Brewer JE, Bennett AD, Gerry AB, Pumphrey NJ, Smethurst DP, Tayton-Martin HK, Lilliam RC, Veloso E, Zheng Z, Badros AZ, ... ... June CH, et al. Adoptive Transfer of Gene-Modified T-Cells Engineered to Express High-Affinity TCRs for Cancer-Testis Antigens (CTAs) NY-ESO-1 or Lage-1, in MM Patients Post Auto-SCT Blood. 120: 472-472. DOI: 10.1182/Blood.V120.21.472.472 |
0.536 |
|
| 2012 |
Halverson D, Mossoba ME, Steinberg SM, blacklock-Schuver B, Hakim FT, Kurlander R, Gea-Banacloche J, Sportes C, Hardy NM, Hickstein DD, Pavletic SZ, Khuu H, Sabatino M, Stroncek D, Leitman SF, ... ... June CH, et al. Pre-Emptive T-Rapa Cell DLI for Therapy of High-Risk Lymphoma After Low-Intensity Allogeneic HCT Blood. 120: 471-471. DOI: 10.1182/Blood.V120.21.471.471 |
0.558 |
|
| 2012 |
Rapoport AP, Aqui NA, Stadtmauer EA, Badros AZ, Vogl DT, Xu Y, Weiss BM, Cai L, Fang H, Veloso E, Zheng Z, Yanovich S, Akpek G, Philip S, Ruehle K, ... ... June CH, et al. Combination Immunotherapy After ASCT for Multiple Myeloma (MM) Using MAGE-A3/Poly-ICLC Immunizations Followed by Vaccine-Primed and Activated Autologous T-Cells Blood. 120: 352-352. DOI: 10.1182/Blood.V120.21.352.352 |
0.478 |
|
| 2012 |
Grupp SA, Porter DL, Teachey DT, Barrett DM, Chew A, Suppa E, Levine BL, Kalos M, June CH. CD19-Redirected Chimeric Antigen Receptor T (CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL-6 Antagonist Tocilizumab (toc). Blood. 120: 2604-2604. DOI: 10.1182/Blood.V120.21.2604.2604 |
0.576 |
|
| 2012 |
Schuster SJ, Aqui NA, Musher B, Levine BL, Andreadis C, Chong EA, Nasta SD, Gordon A, Cotte J, Zheng Z, Brennan AL, Veloso E, June CH. Adoptive Transfer of Autologous CD25-Depleted, CD3/CD28-Costimulated T Cells After Cyclophosphamide - Fludarabine Chemotherapy in Patients with Low-Grade Follicular Lymphoma: Long-Term Follow up Blood. 120: 1631-1631. DOI: 10.1182/Blood.V120.21.1631.1631 |
0.54 |
|
| 2012 |
June CH. Abstract PL03-01: CAR T cells for leukemia and more Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Pl03-01 |
0.628 |
|
| 2012 |
Hassan NJ, Baker D, Harper J, Adams K, Bossi G, Liddy N, Buisson S, Paston S, Gavarret J, Bianchi F, Baston E, Legg A, Ashfield R, McGrath Y, Li Y, ... ... June C, et al. Abstract 3528: IMCmage1: A novel bi-specific biologic re-directing T cells to kill MAGE-A3/A6 presenting cancers Cancer Research. 72: 3528-3528. DOI: 10.1158/1538-7445.Am2012-3528 |
0.483 |
|
| 2012 |
Hassan NJ, Adams K, Bossi G, Harper J, Buisson S, Paston S, Liddy N, Ashfield R, Gavarret J, Bianchi F, Baston E, Baker D, Ladell K, Sewell A, Li Y, ... ... June C, et al. Abstract 3525: IMCgp100: A novel bi-specific biologic for the treatment of malignant melanoma Cancer Research. 72: 3525-3525. DOI: 10.1158/1538-7445.Am2012-3525 |
0.556 |
|
| 2012 |
Barrett DM, Zhao Y, Liu X, Jiang S, Seif AE, Reid GSD, June CH, Grupp SA. Abstract 3505: Preclinical testing of mRNA engineered chimeric antigen receptor T cells: Comparison of a multi-infusion protocol to a single injection of stably expressed CARs in ALL xenograft models Cancer Research. 72: 3505-3505. DOI: 10.1158/1538-7445.Am2012-3505 |
0.571 |
|
| 2011 |
Fecher LA, McGrath Y, Williams DD, Hassan NJ, Kalos M, Schuchter LM, Amaravadi RK, Chew A, Veloso EA, Czerniecki BJ, Karakousis G, Linette GP, Jakobsen BK, June CH. A phase 0 exploratory study to assess the pharmacodynamic effects of single intratumoral dose of a novel bispecific targeting/immune-activating agent on the melanoma tumor microenvironment. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: TPS160. PMID 28023064 DOI: 10.1200/jco.2011.29.15_suppl.tps160 |
0.403 |
|
| 2011 |
Schuster SJ, Hosing C, Shpall EJ, Levine B, Aqui N, Chong EA, Svoboda J, Gordon A, McMannis JD, Bosque D, Cotte J, Brennan A, Zheng Z, Leinbach L, Xu Y, ... ... June CH, et al. Adoptive immunotherapy with autologous CD3/CD28-costimulated T cells after fludarabine-based chemotherapy in patients with chronic lymphocytic leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2557. PMID 28022312 DOI: 10.1200/Jco.2011.29.15_Suppl.2557 |
0.576 |
|
| 2011 |
Frigault MJ, June CH. Predicting cytokine storms: it's about density. Blood. 118: 6724-6. PMID 22194391 DOI: 10.1182/Blood-2011-10-382598 |
0.437 |
|
| 2011 |
Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, ... ... June CH, et al. Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine. 9: 214. PMID 22168571 DOI: 10.1186/1479-5876-9-214 |
0.301 |
|
| 2011 |
Amarnath S, Mangus CW, Wang JC, Wei F, He A, Kapoor V, Foley JE, Massey PR, Felizardo TC, Riley JL, Levine BL, June CH, Medin JA, Fowler DH. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Science Translational Medicine. 3: 111ra120. PMID 22133721 DOI: 10.1126/Scitranslmed.3003130 |
0.528 |
|
| 2011 |
Hardy NM, Mossoba ME, Steinberg SM, Fellowes V, Yan XY, Hakim FT, Babb RR, Avila D, Gea-Banacloche J, Sportès C, Levine BL, June CH, Khuu HM, Carpenter AE, Krumlauf MC, et al. Phase I trial of adoptive cell transfer with mixed-profile type-I/type-II allogeneic T cells for metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6878-87. PMID 21948234 DOI: 10.1158/1078-0432.Ccr-11-1579 |
0.602 |
|
| 2011 |
Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, Almeida JR, Gostick E, Yu Z, Carpenito C, Wang E, Douek DC, Price DA, June CH, Marincola FM, et al. A human memory T cell subset with stem cell-like properties. Nature Medicine. 17: 1290-7. PMID 21926977 DOI: 10.1038/Nm.2446 |
0.53 |
|
| 2011 |
Barrett DM, Seif AE, Carpenito C, Teachey DT, Fish JD, June CH, Grupp SA, Reid GS. Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling. Blood. 118: e112-7. PMID 21856863 DOI: 10.1182/Blood-2011-04-346528 |
0.34 |
|
| 2011 |
Barrett DM, Zhao Y, Liu X, Jiang S, Carpenito C, Kalos M, Carroll RG, June CH, Grupp SA. Treatment of advanced leukemia in mice with mRNA engineered T cells. Human Gene Therapy. 22: 1575-86. PMID 21838572 DOI: 10.1089/Hum.2011.070 |
0.573 |
|
| 2011 |
Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Science Translational Medicine. 3: 95ra73. PMID 21832238 DOI: 10.1126/Scitranslmed.3002842 |
0.658 |
|
| 2011 |
Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. The New England Journal of Medicine. 365: 725-33. PMID 21830940 DOI: 10.1056/Nejmoa1103849 |
0.603 |
|
| 2011 |
Ye Q, Loisiou M, Levine BL, Suhoski MM, Riley JL, June CH, Coukos G, Powell DJ. Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes. Journal of Translational Medicine. 9: 131. PMID 21827675 DOI: 10.1186/1479-5876-9-131 |
0.823 |
|
| 2011 |
Hippen KL, Riley JL, June CH, Blazar BR. Clinical perspectives for regulatory T cells in transplantation tolerance. Seminars in Immunology. 23: 462-8. PMID 21820917 DOI: 10.1016/J.Smim.2011.07.008 |
0.497 |
|
| 2011 |
Butler SL, Valdez H, Westby M, Perros M, June CH, Jacobson JM, Levy Y, Cooper DA, Douek D, Lederman MM, Tebas P. Disease-modifying therapeutic concepts for HIV in the era of highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes (1999). 58: 297-303. PMID 21792065 DOI: 10.1097/Qai.0B013E31822Ccfcc |
0.375 |
|
| 2011 |
Porter DL, Kalos M, Zheng Z, Levine B, June C. Chimeric Antigen Receptor Therapy for B-cell Malignancies. Journal of Cancer. 2: 331-2. PMID 21716851 DOI: 10.7150/Jca.2.331 |
0.434 |
|
| 2011 |
Sterman DH, Haas A, Moon E, Recio A, Schwed D, Vachani A, Katz SI, Gillespie CT, Cheng G, Sun J, Papasavvas E, Montaner LJ, Heitjan DF, Litzky L, Friedberg J, ... ... June CH, et al. A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma. American Journal of Respiratory and Critical Care Medicine. 184: 1395-9. PMID 21642245 DOI: 10.1164/Rccm.201103-0554Cr |
0.34 |
|
| 2011 |
Moon EK, Carpenito C, Sun J, Wang LC, Kapoor V, Predina J, Powell DJ, Riley JL, June CH, Albelda SM. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4719-30. PMID 21610146 DOI: 10.1158/1078-0432.Ccr-11-0351 |
0.571 |
|
| 2011 |
Alagkiozidis I, Facciabene A, Tsiatas M, Carpenito C, Benencia F, Adams S, Jonak Z, June CH, Powell DJ, Coukos G. Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy. Journal of Translational Medicine. 9: 77. PMID 21609494 DOI: 10.1186/1479-5876-9-77 |
0.381 |
|
| 2011 |
Hippen KL, Merkel SC, Schirm DK, Sieben CM, Sumstad D, Kadidlo DM, McKenna DH, Bromberg JS, Levine BL, Riley JL, June CH, Scheinberg P, Douek DC, Miller JS, Wagner JE, et al. Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Science Translational Medicine. 3: 83ra41. PMID 21593401 DOI: 10.1126/Scitranslmed.3001809 |
0.593 |
|
| 2011 |
Hippen KL, Merkel SC, Schirm DK, Nelson C, Tennis NC, Riley JL, June CH, Miller JS, Wagner JE, Blazar BR. Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 11: 1148-57. PMID 21564534 DOI: 10.1111/J.1600-6143.2011.03558.X |
0.599 |
|
| 2011 |
Song DG, Ye Q, Carpenito C, Poussin M, Wang LP, Ji C, Figini M, June CH, Coukos G, Powell DJ. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Research. 71: 4617-27. PMID 21546571 DOI: 10.1158/0008-5472.Can-11-0422 |
0.628 |
|
| 2011 |
Wilen CB, Wang J, Tilton JC, Miller JC, Kim KA, Rebar EJ, Sherrill-Mix SA, Patro SC, Secreto AJ, Jordan AP, Lee G, Kahn J, Aye PP, Bunnell BA, Lackner AA, ... ... June CH, et al. Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases. Plos Pathogens. 7: e1002020. PMID 21533216 DOI: 10.1371/Journal.Ppat.1002020 |
0.458 |
|
| 2011 |
Ertl HC, Zaia J, Rosenberg SA, June CH, Dotti G, Kahn J, Cooper LJ, Corrigan-Curay J, Strome SE. Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010. Cancer Research. 71: 3175-81. PMID 21531763 DOI: 10.1158/0008-5472.Can-10-4035 |
0.518 |
|
| 2011 |
Kohn DB, Dotti G, Brentjens R, Savoldo B, Jensen M, Cooper LJ, June CH, Rosenberg S, Sadelain M, Heslop HE. CARs on track in the clinic. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 432-8. PMID 21358705 DOI: 10.1038/Mt.2011.1 |
0.479 |
|
| 2011 |
Cannon P, June C. Chemokine receptor 5 knockout strategies Current Opinion in Hiv and Aids. 6: 74-79. PMID 21242897 DOI: 10.1097/Coh.0B013E32834122D7 |
0.48 |
|
| 2011 |
Bishop MR, Alyea EP, Cairo MS, Falkenburg JH, June CH, Kröger N, Little RF, Miller JS, Pavletic SZ, Porter DL, Riddell SR, van Besien K, Wayne AS, Weisdorf DJ, Wu RS, et al. National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 17: 443-54. PMID 21224011 DOI: 10.1016/J.Bbmt.2010.12.713 |
0.309 |
|
| 2011 |
Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Fang HB, Cai L, Janofsky S, Chew A, Storek J, Akpek G, Badros A, Yanovich S, Tan MT, Veloso E, Pasetti MF, ... ... June CH, et al. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood. 117: 788-97. PMID 21030558 DOI: 10.1182/Blood-2010-08-299396 |
0.555 |
|
| 2011 |
Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, Defor T, Levine BL, June CH, Rubinstein P, McGlave PB, Blazar BR, Wagner JE. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 117: 1061-70. PMID 20952687 DOI: 10.1182/Blood-2010-07-293795 |
0.503 |
|
| 2011 |
Stadtmauer EA, Vogl DT, Luning Prak E, Boyer J, Aqui NA, Rapoport AP, McDonald KR, Hou X, Murphy H, Bhagat R, Mangan PA, Chew A, Veloso EA, Levine BL, Vonderheide RH, ... ... June CH, et al. Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial. Blood. 117: 63-71. PMID 20864577 DOI: 10.1182/Blood-2010-07-296822 |
0.483 |
|
| 2011 |
Grupp SA, June CH. Adoptive cellular therapy. Current Topics in Microbiology and Immunology. 344: 149-72. PMID 20700700 DOI: 10.1007/82_2010_94 |
0.51 |
|
| 2011 |
Ando J, Ngo MC, Ennamuri S, Sun J, Heslop HE, Bollard CM, June CH, Leen AM, Gottschalk S, Rooney CM. Towards Phase 2/3 Trials for Epstein - Barr Virus (EBV)-Associated Malignancies, Blood. 118: 4043-4043. DOI: 10.1182/Blood.V118.21.4043.4043 |
0.594 |
|
| 2011 |
Hexner E, Luger SM, Mangan JK, Frey NV, Jeschke GR, Frank D, Reshef R, Loren AW, Goldstein SC, Rosenbach M, Nowaczyk C, Schuster M, Stadtmauer EA, Levine BL, June CH, et al. A Phase 1 Dose Escalation Study of Infusion of Ex Vivo CD3/CD28 Costimulated Umbilical Cord Blood-Derived T Cells in Adults Undergoing Transplantation for Advanced Hematologic Malignancies Blood. 118: 3032-3032. DOI: 10.1182/Blood.V118.21.3032.3032 |
0.581 |
|
| 2011 |
Song D, Canevari S, June C, Coukos G, Powell DJ. Abstract LB-156: Improved T cell survival, tumor localization and tumor eradication by folate receptor-alpha redirected T cells is achieved by provision of CD137 costimulatory signaling Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-156 |
0.595 |
|
| 2011 |
Harper JV, Hassan NJ, Liddy N, Mahon T, Bossi G, Adams K, Gavarret J, Bianchi F, Lissin N, Molloy P, Li Y, Pumphrey N, Cameron B, Sami M, Baston E, ... ... June C, et al. Abstract 4744: Soluble, high affinity TCRs fused to anti-CD3 redirect T cells to kill cancer cells presenting MAGE-A3 and NY-ESO antigens Cancer Research. 71: 4744-4744. DOI: 10.1158/1538-7445.Am2011-4744 |
0.491 |
|
| 2011 |
Paston SJ, Ashfield R, Liddy N, Bossi G, Adams K, McCormack E, Lissina A, Mahon T, Hassan N, Gavarret J, Bianchi F, Pumphrey N, Ladell K, Gostick E, Sewell AK, ... ... June C, et al. Abstract 1787: ImmTACs: Bi-functional reagents for redirected tumour cell killing Cancer Research. 71: 1787-1787. DOI: 10.1158/1538-7445.Am2011-1787 |
0.577 |
|
| 2011 |
Ertl HCJ, Zaia J, Rosenberg SA, June CH, Dotti G, Kahn J. Considerations for the clinical application of chimeric antigen receptor T cells: Observations from a Recombinant DNA Advisory Committee symposium held June 15, 2010 (Cancer Research (2011) 71, (3175-3181)) Cancer Research. 71: 4325. DOI: 10.1158/0008-5472.Can-11-1396 |
0.463 |
|
| 2011 |
Tebas P, Wilsen C, Doms R, Hoxie J, Gregory P, Holmes M, June C. 176 Exploring the Potential of CCR5 and CXCR4 Modified CD4 T Cells to Target the HIV-1 Reservoir Jaids Journal of Acquired Immune Deficiency Syndromes. 56: 73. DOI: 10.1097/01.Qai.0000397359.53545.66 |
0.5 |
|
| 2011 |
Fowler DH, Mossoba ME, Hakim FT, Kurlander R, Gea-Banacloche J, Sportes C, Hardy NM, Pavletic SZ, Steinberg SM, Khuu HM, Sabatino M, Stroncek DF, Leitman SF, Rowley SD, Donato M, ... ... June CH, et al. T-Rapa Cell DLI Safely Balances Th1/Th2 Cytokine Activation After Low-Intensity Allogeneic Hematopoietic Cell Transplantation Biology of Blood and Marrow Transplantation. 17. DOI: 10.1016/J.Bbmt.2010.12.023 |
0.459 |
|
| 2010 |
Paulos CM, Carpenito C, Plesa G, Suhoski MM, Varela-Rohena A, Golovina TN, Carroll RG, Riley JL, June CH. The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells. Science Translational Medicine. 2: 55ra78. PMID 20980695 DOI: 10.1126/Scitranslmed.3000448 |
0.848 |
|
| 2010 |
Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL, Albelda SM, June CH. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Research. 70: 9053-61. PMID 20926399 DOI: 10.1158/0008-5472.Can-10-2880 |
0.564 |
|
| 2010 |
Boise LH, Minn AJ, Noel PJ, June CH, Accavitti MA, Lindsten T, Thompson CB. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL. Immunity. 1995. 3: 87-98. Journal of Immunology (Baltimore, Md. : 1950). 185: 3788-99. PMID 20858890 |
0.461 |
|
| 2010 |
Sluijter BJ, van den Hout MF, Stam AG, Lougheed SM, Suhoski MM, van den Eertwegh AJ, van den Tol MP, van Leeuwen PA, Meijer S, Scheper RJ, June CH, de Gruijl TD, Santegoets SJ. 4-1BB-mediated expansion affords superior detection of in vivo primed effector memory CD8+ T cells from melanoma sentinel lymph nodes. Clinical Immunology (Orlando, Fla.). 137: 221-33. PMID 20708974 DOI: 10.1016/J.Clim.2010.07.009 |
0.842 |
|
| 2010 |
Zhou Q, Munger ME, Highfill SL, Tolar J, Weigel BJ, Riddle M, Sharpe AH, Vallera DA, Azuma M, Levine BL, June CH, Murphy WJ, Munn DH, Blazar BR. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood. 116: 2484-93. PMID 20570856 DOI: 10.1182/Blood-2010-03-275446 |
0.451 |
|
| 2010 |
Amarnath S, Flomerfelt FA, Costanzo CM, Foley JE, Mariotti J, Konecki DM, Gangopadhyay A, Eckhaus M, Wong S, Levine BL, June CH, Fowler DH. Rapamycin generates anti-apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD. Autophagy. 6: 523-41. PMID 20404486 DOI: 10.4161/Auto.6.4.11811 |
0.539 |
|
| 2010 |
Cairo MS, Jordan CT, Maley CC, Chao C, Melnick A, Armstrong SA, Shlomchik W, Molldrem J, Ferrone S, Mackall C, Zitvogel L, Bishop MR, Giralt SA, June CH. NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 16: 709-28. PMID 20227509 DOI: 10.1016/J.Bbmt.2010.03.002 |
0.342 |
|
| 2010 |
Bishop MR, Alyea EP, Cairo MS, Falkenburg JH, June CH, Kröger N, Little RF, Miller JS, Pavletic SZ, Porter D, Riddell SR, van Besien K, Wayne AS, Weisdorf DJ, Wu R, et al. Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 16: 563-4. PMID 20202482 DOI: 10.1016/J.Bbmt.2010.02.025 |
0.351 |
|
| 2010 |
Amarnath S, Costanzo CM, Mariotti J, Ullman JL, Telford WG, Kapoor V, Riley JL, Levine BL, June CH, Fong T, Warner NL, Fowler DH. Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1. Plos Biology. 8: e1000302. PMID 20126379 DOI: 10.1371/Journal.Pbio.1000302 |
0.439 |
|
| 2010 |
Paulos CM, June CH. Putting the brakes on BTLA in T cell-mediated cancer immunotherapy. The Journal of Clinical Investigation. 120: 76-80. PMID 20038807 DOI: 10.1172/Jci41811 |
0.61 |
|
| 2010 |
Tammana S, Huang X, Wong M, Milone MC, Ma L, Levine BL, June CH, Wagner JE, Blazar BR, Zhou X. 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Human Gene Therapy. 21: 75-86. PMID 19719389 DOI: 10.1089/Hum.2009.122 |
0.65 |
|
| 2010 |
Hardy NM, Fellowes V, Rose J, Fowler DH, Gress RE, Levine BL, June CH, Hakim FT, Bishop MR. Costimulated, Tumor-Derived Donor Lymphocyte (TDL) Infusion for B-Cell Tumor Relapse After Allogeneic Hematopoietic Stem Cell Transplantation Blood. 116: 683-683. DOI: 10.1182/Blood.V116.21.683.683 |
0.527 |
|
| 2010 |
Fowler DH, Mossoba ME, Schuver BB, Layton P, Hakim FT, Kurlander R, Gea-Banacloche J, Sportes C, Hardy NM, Pavletic SZ, Steinberg SM, Khuu H, Sabatino M, Stroncek D, Leitman S, ... ... June CH, et al. Adoptive Transfer of Treg-Depleted Donor Th1 and Th2 Cells Safely Accelerates Alloengraftment After Low-Intensity Chemotherapy Blood. 116: 521-521. DOI: 10.1182/Blood.V116.21.521.521 |
0.554 |
|
| 2010 |
Mossoba ME, Mariotti J, Yan X, Gangopadhyay A, Winterton M, Sabatino M, Khuu H, Fellowes V, Hakim FT, Stroncek D, Leitman S, Levine BL, June CH, Fowler DH. T-Rapa Cell Clinical Products Contain a Balance of Minimally Differentiated Th2/Th1 Effector Cells Depleted of Treg Cells Blood. 116: 352-352. DOI: 10.1182/Blood.V116.21.352.352 |
0.53 |
|
| 2010 |
Barrett DM, Seif AE, Carpenito C, Strong EP, June CH, Grupp SA, Reid GSD. Bioluminescent Tracking of Human and Mouse Acute Lymphoblastic Leukemia Reveals Potent Immunogenicity of Luciferase In Some Preclinical Models of Leukemia Blood. 116: 2140-2140. DOI: 10.1182/Blood.V116.21.2140.2140 |
0.386 |
|
| 2010 |
Hassan NJ, Liddy N, Mahon T, Bossi G, Adams K, Gavarret J, Bianchi F, Lissin N, Molloy P, Li Y, Pumphrey N, Cameron B, Sami M, Baston E, Harper J, ... ... June C, et al. Abstract 5616: Soluble, high affinity TCRs fused to anti-CD3 redirect T cells to kill cancer cells presenting MAGE-A3 and NY-ESO antigens Cancer Research. 70: 5616-5616. DOI: 10.1158/1538-7445.Am10-5616 |
0.491 |
|
| 2010 |
Barrett DM, Carpenito C, Zhao YB, Kalos M, June CH, Grupp SA. Abstract 2933: Pre-clinical model of eradication of B cell leukemia with lentiviral transduced anti-CD19 chimeric immunoreceptor-modified T cells Cancer Research. 70: 2933-2933. DOI: 10.1158/1538-7445.Am10-2933 |
0.572 |
|
| 2010 |
Amarnath S, Mangus C, Costanzo C, Foley J, Eckhaus M, Levine B, June C, Fowler D. Human T Cell Rapamycin Resistance And Th1/Tc1 Polarization Augment Xenogeneic Graft-Versus-Host Disease Biology of Blood and Marrow Transplantation. 16: S304. DOI: 10.1016/J.Bbmt.2009.12.444 |
0.389 |
|
| 2009 |
Alagkiozidis I, Facciabene A, Carpenito C, Benencia F, Jonak Z, Adams S, Carroll RG, Gimotty PA, Hammond R, Danet-Desnoyers GÄ, June CH, Powell DJ, Coukos G. Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18. Journal of Translational Medicine. 7: 104. PMID 20003308 DOI: 10.1186/1479-5876-7-104 |
0.383 |
|
| 2009 |
June CH, Blazar BR, Riley JL. Engineering lymphocyte subsets: tools, trials and tribulations. Nature Reviews. Immunology. 9: 704-16. PMID 19859065 DOI: 10.1038/Nri2635 |
0.367 |
|
| 2009 |
Nakazawa Y, Huye LE, Dotti G, Foster AE, Vera JF, Manuri PR, June CH, Rooney CM, Wilson MH. Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes. Journal of Immunotherapy (Hagerstown, Md. : 1997). 32: 826-36. PMID 19752751 DOI: 10.1097/Cji.0B013E3181Ad762B |
0.597 |
|
| 2009 |
Zhou Q, Bucher C, Munger ME, Highfill SL, Tolar J, Munn DH, Levine BL, Riddle M, June CH, Vallera DA, Weigel BJ, Blazar BR. Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. Blood. 114: 3793-802. PMID 19724059 DOI: 10.1182/Blood-2009-03-208181 |
0.481 |
|
| 2009 |
Rapoport AP, Stadtmauer EA, Aqui N, Vogl D, Chew A, Fang HB, Janofsky S, Yager K, Veloso E, Zheng Z, Milliron T, Westphal S, Cotte J, Huynh H, Cannon A, ... ... June CH, et al. Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4499-507. PMID 19509133 DOI: 10.1158/1078-0432.Ccr-09-0418 |
0.577 |
|
| 2009 |
Riley JL, June CH, Blazar BR. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity. 30: 656-65. PMID 19464988 DOI: 10.1016/J.Immuni.2009.04.006 |
0.54 |
|
| 2009 |
Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, Samanta M, Lakhal M, Gloss B, Danet-Desnoyers G, Campana D, Riley JL, Grupp SA, June CH. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 1453-64. PMID 19384291 DOI: 10.1038/Mt.2009.83 |
0.6 |
|
| 2009 |
Wang GP, Levine BL, Binder GK, Berry CC, Malani N, McGarrity G, Tebas P, June CH, Bushman FD. Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 844-50. PMID 19259065 DOI: 10.1038/Mt.2009.16 |
0.437 |
|
| Show low-probability matches. |